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Abstract

EFFECTS OF CANNABINOIDS ON PAIN-STIMULATED
AND PAIN-DEPRESSED BEHAVIOR IN RATS
By Andrew J. Kwilasz, BA, Psychology
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2013.
Major Director: Dr. S. Stevens Negus, PhD, Professor,
Department of Pharmacology and Toxicology
Cannabinoids produce antinociception in many preclinical models of acute and chronic
pain. In contrast, cannabinoids produce inconsistent analgesia in humans, showing little
or no efficacy in treating acute pain, with modest efficacy in treating chronic
inflammatory pain. This discrepancy may reflect an overreliance on preclinical assays of
pain-stimulated behaviors, defined as behaviors that increase in rate or intensity
following delivery of a noxious stimulus. In these assays, antinociception is indicated by
a reduction in pain-stimulated behaviors, and antinociception is produced either by a
reduction in sensory sensitivity to the noxious stimulus (i.e. true analgesia) or by false
positive

motor

impairment.

This

dissertation

addresses

this

weakness

by

complementing cannabinoid effects in conventional assays of pain-stimulated behavior
with their effects in novel assays of pain-depressed behavior. Pain-depressed behaviors
are defined as behaviors that decrease in rate or intensity following presentation of a
noxious stimulus. Motor impairment does not produce false positive antinociception in
assays of pain-depressed behavior, because antinociception is indicated by a blockade
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or reversal of pain-induced behavioral depression. In this dissertation, an intraperitoneal
(IP) injection of lactic acid served as an acute noxious stimulus to stimulate stretching
(pain-stimulated behavior) or depress intracranial self-stimulation (ICSS) (paindepressed behavior), whereas, IP injection(s) of lipopolysaccharide (LPS) served as a
chronic/acute inflammatory-related noxious stimulus to stimulate mechanical allodynia
(pain-stimulated behavior) or depress ICSS (pain-depressed behavior). Cannabinoids
tested in the assays of acid-stimulated stretching and acid-depressed ICSS included:
mixed CB1R/CB2R agonists THC and CP55940, drugs that modulate levels of the
endogenous cannabinoid agonist anandamide (URB597 and PF3845), and a selective
CB2R agonist, GW405833. THC was also tested in assays of LPS-stimulated
mechanical allodynia and LPS-depressed ICSS. In general, mixed CB1R/CB2R
agonists were ineffective or exacerbated pain-depressed behavior regardless of noxious
stimulus. Contrastingly, URB597 and GW405833 produced antinociception in the assay
of acid-depressed ICSS; however their effects were not mediated by CBRs. All
compounds produced antinociception in the assay of pain-stimulated behavior, except
for PF3845. These results suggest that assays of pain-depressed behavior may be
useful for development of cannabinoid analgesic medications, but that further research
is needed to determine mechanisms underlying cannabinoid-mediated antinociception
in these assays.

1
CHAPTER ONE
Introduction and Background

1.1 Use of cannabinoids for the treatment of pain
The marijuana plant (Cannabis sativa) is a natural source of cannabinoids used
for centuries to treat pain (Mechoulam and Ben-Shabat, 1999). Δ9-tetrahydrocannabinol
(THC), the primary active constituent of marijuana, has been studied extensively with
the intent of characterizing its therapeutic properties. Many cannabinoids originate from
the marijuana plant and are classified by their structural relationship to THC, whereas
synthetically developed cannabinoids are classified by their activity at cannabinoid
receptors (Weissman, 1981). Moreover, endogenous ligands for cannabinoid receptors
have been identified and are also classified as cannabinoids. Most of THC’s behavioral
effects are exerted through its action as a low-efficacy agonist at the cannabinoid-1
receptor (CB1R) (Devane et al., 1988; Melvin et al., 1993; Onaivi et al., 1995); however,
in addition to CB1Rs, THC also activates the cannabinoid-2 receptor (CB2R) (Felder et
al. 1995). As a result of discovery of THC’s pharmacological actions, several mixed
synthetic cannabinoid agonists for CB1Rs and CB2Rs have been developed (Howlett
1995). Moreover, selective agonists have been developed for CB1Rs and CB2Rs, such
as Arachidonyl-2’-chloroethylamide (ACEA) (Hillard et al., 1999) and GW405833
(Marriot and Huffman, 2008), respectively.
THC and other mixed CB1R/CB2R agonists are highly efficacious in nearly all
preclinical assays of pain. For example, studies modeling acute nociception have shown
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that THC and other CBR agonists such as CP55940, WIN55212-2, and HU210 are all
effective at increasing the latency to paw withdrawal on a hot plate in rats (De Vry et al.,
2004; Hama and Sagen, 2009). Other studies using tail-flick assays to measure spinal
reflexes elicited by noxious thermal stimuli have found similar results (Rubino et al.,
1994; Patrini et al., 1997; Wiley et al., 2007), as have studies using models of acute
inflammatory pain such as stimulation of stretching by intraperitoneal (IP) injection of
dilute acid (Sofia et al., 1975; Booker et al., 2009) or stimulation of paw flinching by
intraplantar administration of dilute formalin (Finn et al., 2004; Khodayar et al., 2006).
THC and CBR agonists have also been shown to produce antinociception in preclinical
models of chronic pain, such as those that model inflammatory or neuropathic pain (Lim
et al., 2003; Hsieh et al., 2011). For example, an intraplantar injection of Complete
Freund’s Adjuvant (CFA) into the rat hindpaw produces a transient inflammatory
reaction accompanied by paw swelling and hypersensitive paw-withdrawal from
mechanical and thermal stimuli occurring as early as 24 h after injection and lasting up
to two weeks (Schepers et al. 2008a; Schepers et al. 2008b; Yang and Gao 2010).
Several studies have demonstrated the effectiveness of cannabinoids in attenuating
CFA-induced inflammation and associated nociceptive responses (Amaya et al. 2006;
Jayamanne et al. 2006). Furthermore, chronic pain has been associated with
neuropathy in humans, and neuropathic pain has been modeled in rodents using
procedures (e.g. nerve injury or chemotherapeutic drug treatment like paclitaxel) that
measure hypersensitive withdrawal responses from mechanical or thermal stimuli.
Cannabinoids often produce antinociception in these assays manifested as a blockade
of neuropathy-induced hypersensitivity (Costa et al., 2004; Pascual et al., 2005).
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Selective CB2R agonists also decrease pain-related behaviors in many preclinical
studies (Wilkerson and Milligan, 2011). For example, selective CB2R agonists are
effective at increasing the latency of time for a rat to withdraw its paw from an
innocuous mechanical stimulus or noxious thermal stimulus after acute tissue damage
(i.e. paw incision) as well as after other inflammatory (i.e. intraplantar CFA) or nerverelated injuries (Malan et al., 2001; Valenzano et al., 2005; Whiteside et al., 2005; Hsieh
et al., 2011). Moreover, CB2R agonists have been shown to be more potent against
inflammatory-related stimuli such an intraplantar injection of CFA versus an acute tissue
injury such as intraplantar paw incision (Valenzano et al., 2005). One potential
advantage of CB2R agonists is that they do not produce CB1R-mediated side effects
such as behavioral depression/sedation and abuse-related effects, and this property
makes the CB2R an attractive target for candidate cannabinoid analgesics (Marriott and
Huffman, 2008).
The endogenous cannabinoid system, or endocannabinoid system, has also
gained considerable attention as a target to treat pain and inflammation (Pacher et al.,
2006; Schlosburg et al., 2009; Alvarez-Jaimes and Palmer, 2011). The
endocannabinoid system is comprised primarily of two endogenous cannabinoid ligands
for CB1Rs and CB2Rs, anandamide (AEA) and 2-arachidonylglycerol (2-AG), and the
respective enzymes that degrade them, fatty acid amide hydrolase (FAAH) and
monoacylglycerol lipase (MAGL). In particular, the inhibition of FAAH, which has the
effect of increasing endogenous levels of AEA in synapses, has been demonstrated as
a promising alternative to CB1R agonist-based cannabinoid medications (Pacher et al.,
2006; Schlosburg et al., 2009; Alvarez-Jaimes and Palmer, 2011). FAAH inhibitors such
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as URB597 and PF3845 produce antinociception in many assays of preclinical pain
(Jayamanne et al., 2006; Ahn et al., 2009; Clapper et al., 2010; Kinsey et al., 2010;
Booker et al., 2012; Ghosh et al., 2012). Furthermore, FAAH inhibitors are a useful
strategy to reduce side effects associated with the CB1R, as FAAH inhibitors increase
CBR activity only when and where endogenous AEA is actively being synthesized and
released from cells. This property of FAAH inhibitors imbues them with temporal and
spatial selectivity for activation of CBRs not obtainable with direct CBR agonists (Pacher
et al., 2006; Schlosburg et al., 2009; Alvarez-Jaimes and Palmer, 2011). FAAH
inhibitors have also been shown to increase other anti-inflammatory fatty acid
ethanolamines, such as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA),
which activate peroxisome proliferator-activated receptor-alpha (PPAR-α) (Pacher et al.,
2006; Schlosburg et al., 2009; Alvarez-Jaimes and Palmer, 2011). PPAR-α activation
alone produces antinociception in several preclinical models of pain (Russo et al., 2007;
Costa et al., 2008; Clapper et al., 2010), and has also been shown to reduce nociceptor
field size and paw oedema in rat and mouse models of inflammatory pain (Clapper et al.
2010; Sagar et al. 2008). Overall, the preclinical literature provides abundant support for
the antinociceptive effects of FAAH inhibitiors mediated by both CBRs and PPAR-α.
Despite the overwhelming evidence of the antinociceptive capabilities of CBR
agonists in preclinical studies, CBR agonists have not been as successful in wellcontrolled clinical studies (Rice, 2006; Karst et al., 2010). Most of the studies on CBR
agonists in humans have investigated either smoked marijuana and/or THC, including
its synthetic forms marinol or dronabinol. Smoked marijuana and oral THC have
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displayed some weak efficacy at treating various forms of acute nociception (Greenwald
and Stitzer, 2000; Wallace et al., 2007; Cooper et al., 2013); however other studies
investigating effects of THC and other CBR agonists on acute inflammatory conditions
such as post-operative pain and experimentally-induced sunburn have displayed
virtually no efficacy, with pain exacerbated by higher doses in some studies (Raft et al.,
1977; Buggy et al., 2003; Naef et al., 2003; Beaulieu, 2006; Kraft et al., 2008; Klooker et
al., 2011). A single clinical study has been conducted demonstrating the ability of
Sativex (a formulation of THC and a non-psychoactive cannabinoid cannabidiol in a
sublingual spray) to relieve morning pain at rest and during movement in patients with
chronic inflammatory pain associated with rheumatoid arthritis (Blake et al., 2006), and
Sativex is also approved in several countries to treat muscle spasticity and related pain
in another inflammatory disorder, multiple sclerosis (Leussink et al., 2012). Additionally,
some clinical trials exist that support weak efficacy of CBR agonists for the treatment of
various types of neuropathic pain, although other studies fail to show improvement in
symptoms (Berman et al., 2004; Svendsen et al., 2004; Abrams et al., 2007; Nurmikko
et al., 2007; Rog et al., 2007; Ellis et al., 2009). Recently, clinical trials have been
conducted to test the efficacy of the FAAH inhibitor PF7845 for the treatment of
osteoarthritis-related pain (Huggins et al., 2012) and the efficacy of the selective CB2R
agonist GW842166 (Ostenfeld et al., 2011) for the treatment of dental pain; however
neither of these compounds displayed analgesic efficacy in these studies. Several other
CB2R agonists are also in various phases of clinical development (see Wilkerson and
Milligan, 2011). Taken together, these studies demonstrate that although CBR agonists
may have some efficacy to relieve certain forms of chronic pain, further studies are

6
needed to determine the specific pathologies/circumstances in which CBR agonists as
analgesic medications are most useful.
In summary, there is a discordance between the robust and reliable
antinociceptive effects of CBs in preclinical studies and the lack of consistent analgesic
effects in the clinic, especially under conditions of acute pain. This discordance may
reflect an overreliance of preclinical research on assays that measure pain-stimulated
behavior, as explained in section 1.3.

1.2. Cannabinoid receptor pharmacology
The CBR system consists of at least two known receptors: CB1R and CB2R.
CBRs are G-protein-coupled receptors coupled to Gi/o (Howlett, 2002; Demuth and
Molleman, 2006; Lovinger, 2008). Activation of CBRs causes dissociation of Gα and Gβγ
subunits from the G-protein coupled receptor. The Gα subunit decreases activity of
adenylyl cyclase activity, which subsequently decreases production of cyclic adenosine
monophosphate (cAMP) (Howlett et al., 1990). Decreased cAMP has been shown to
lead to decreased protein kinase A activity, which subsequently leads to increased
activity of G-protein coupled inwardly-rectifying and A-type potassium channels and
decreased probability of the cell firing (Mackie et al., 1995; McAllister et al., 1999).
Moreover, the Gβγ subunit causes decreased activity of N- and P/Q-type calcium
channels and subsequently decreases probability of neurotransmitter release,
regardless of whether an action potential occurs (Mackie et al., 1995; De Waard et al.,
2005).
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CB1Rs are the most abundant receptors in the mammalian central nervous
system; however they are also present in peripheral tissues at much lower levels
(Pacher et al., 2006). CB1Rs are typically located on the presynaptic axon terminals of
glutamatergic and gamma-aminobutyric acid (GABA)-ergic neurons. When glutamate or
GABA are released from these neurons, “on demand” endogenous biosynthesis and
release of endocannabinoids occurs in the post-synaptic cell. Once released,
endocannabinoid agonists such as AEA and 2-AG travel retrogradely back across the
synapse to bind and activate presynaptically-located CB1Rs, which serves as a
negative feedback mechanism of glutamate and GABA release (Figure 1.1) (Ahn et al.,
2008). Moreover, CB1R activation has been shown to lead to short-term depression
(STD) and long-term depression (LTD) of glutamatergic synapses and GABAergic
synapses (Kano et al., 2009; Peterfi et al., 2012). Endocannabinoid-mediated LTD is a
phenomenon by which signaling at the CB1R decreases future probability of glutamate
or GABA release, and is a form of synaptic plasticity, which serves to weaken synaptic
connections. CB1R agonists and more commonly endocannabinoids such as AEA and
2-AG have been shown to elicit LTD (Mackie, 2006). In addition to regulating LTD via
CB1Rs, AEA has also been shown to regulate LTD via activation of transient receptor
potential vanilloid-1 (TRPV1) ion channels (Chavez et al., 2010; Di Marzo, 2010;
Grueter et al., 2010). CB1Rs have been found on primary afferent nociceptors and are
distributed on their cell bodies, their peripheral terminals in various tissues, and their
central terminals in the spinal cord (Veress et al., 2012). Furthermore, CB1Rs are
distributed in brain regions associated with pain processing such as the prefrontal
cortex (PFC), periaqueductal gray (PAG), and amygdala (Amg) (Hohmann et al., 1999;
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Hohmann and Herkenham, 1999). CB1Rs are also present in brain regions related to
reward and motivated behavior, such as the nucleus accumbens (NAc) and ventral
tegmental area (VTA) (Herkenham et al., 1991), and these brain regions may also play
a role in the experience of pain and expression of pain-related behaviors (Jarcho et al.,
2012). Given the wide distribution of CB1Rs in the central nervous system, CB1Rmediated effects of CBR agonists on pain processing are vast, having the potential
ability to modulate afferent pain signals and inflammation as well as other affective
signs of pain (Figure 1.2) (Smith et al., 2001; Pacher et al., 2006). Cannabinoid agonists
and/or endocannabinoids have also been shown to induce LTD at synapses between
primary nociceptors and secondary nociceptors or between primary nociceptors and
motor neurons (Yuan and Burrell, 2010; Kato et al., 2012; Yuan and Burrell, 2012; Yuan
and Burrell, 2013), as well as in brain regions such as the VTA, NAc, and hippocampus
(Chavez et al., 2010; Di Marzo, 2010; Grueter et al., 2010; Kortleven et al., 2011; Peterfi
et al., 2012; Labouebe et al., 2013). LTD occurring in physiological regions such as
these may also contribute to long-term modulation of afferent pain signals. The
abundance of CB1Rs in the central nervous system are also responsible for the large
number of side effects caused by CB1R agonists, including sedation, memory- and
cognitive- deficits, as well as the potential for abuse (Kaufmann et al., 2010). Overall,
these side effects as well as others have dampened enthusiasm for direct CB1R
agonists as candidate analgesic drugs (Karst and Wippermann, 2009).
In contrast to CB1Rs, CB2Rs have been found primarily on immune-related cells,
and were traditionally thought to only be expressed in peripheral tissues (Massi et al.,
2006; Schlosburg et al., 2009; Alvarez-Jaimes and Palmer, 2011). More recently,
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studies have found CB2Rs expressed in the central nervous system (Svizenska et al.,
2008; Alvarez-Jaimes and Palmer, 2011). Although some studies have shown the
presence of CB2Rs on neurons (Svizenska et al., 2008), most CB2Rs receptors
expressed in the central nervous system are thought to be on immune system cells,
primarily microglia (Cabral et al., 2008; Wilkerson and Milligan, 2011). Microglia are
cells that become primed and then activated by pro-inflammatory molecules, such as
cytokines, which are released as a result of ongoing inflammation. During the primed
phase, microglia have been shown to express a high number of CB2Rs, and activation
of these CB2Rs can inhibit migration and activation of the microglial cells (Cabral et al.,
2008). Once activated, however, microglia release pro-inflammatory molecules,
participating in a positive feedback mechanism of inflammation that is insensitive to
CB2R agonists (Cabral et al., 2008; Milligan and Watkins, 2009; Wilkerson and Milligan,
2011). The effects of CB2R agonists are not as well-characterized as effects of CB1R
agonists; however, CB2R agonists are thought to exert their antinociceptive properties
at least in part through inhibition of the microglial response to inflammation (Figure 1.3)
(Wilkerson and Milligan, 2011).
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Figure 1.1

Figure 1.1. Depiction of a synapse with presynaptically-located CB1Rs. Displays
biosynthetic and degradation pathways for AEA, and the effects of CB1R agonists or
FAAH inhibition on glutamate or GABA release from a synapse due to noxious
stimulation. AEA’s biosynthetic pathway is not fully understood but can involve cleavage
of the phospholipid precursor N-arachidonoylphosphatidylethanolamine (NAPE) from
the cell membrane by the enzyme NAPE-phospholipase D (NAPE-PLD), whereas other
biosynthetic pathways have been shown to involve cleavage via phospholipase C (PLC)
and phosphatase (Liu et al., 2006). CBR agonists such as THC and CP55940 act
directly at the CB1R to inhibit neurotransmitter release, whereas FAAH inhibitors such
as URB597 and PF3845 act indirectly by inhibiting the degradation of AEA into
ethanolamine and arachidonic acid (AA) by FAAH, causing increased AEA levels and
subsequent CB1R activation (Ahn et al., 2008).
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Figure 1.2

Figure 1.2. Depicts the primary pain pathway and its interaction with CB1Rs, as well as
the ability of pain signals to influence brain areas regulating reward and emotion.
Primary afferents synapse with secondary afferents in the dorsal horn of the spinal cord.
Secondary afferents then synapse with tertiary afferents in the thalamus, and also send
collateral projections to lower brain areas such as the rostral ventromedial medulla
(RVM), the periaqueductal gray (PAG), and the lateral hypothalamus (LH). Tertiary
synapses finally terminate in cortical areas. Furthermore, secondary nociceptors also
send projections to the parabrachial nucleus (PBN), which then project to areas
involved in reward and emotion such as the ventral tegmental area (VTA) and amygdala
(Amg), both of which also synapse with the nucleus accumbens (NAc) (Rice, 2006).
CB1Rs have been found in every brain region depicted in this figure (Herkenham et al.,
1991; Mailleux and Vanderhaeghen, 1992; Hohmann et al., 1999; Hohmann and
Herkenham, 1999) and thus have the ability to partake in modulation of pain signals at
many different stages of pain processing.
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Figure 1.3

Figure 1.3. Depiction of microglial cells expressing CB2Rs. A noxious stimulus may
produce tissue damage and subsequent release of pro-inflammatory molecules such as
cytokines. These pro-inflammatory molecules serve to “prime” the microglial cells,
causing them to express a large number of CB2Rs and migrate toward areas of
inflammation. CB2R agonists can bind directly to CB2Rs on microglial cells and inhibit
this migration as well as subsequent activation of microglial cells (Cabral et al., 2008),
whereas FAAH inhibitors such as URB597 and PF3845 act indirectly by inhibiting the
degradation of AEA into ethanolamine and arachidonic acid (AA) by FAAH, causing
increased AEA levels and subsequent CB2R activation (Ahn et al., 2008). 2-AG may
also be released by microglia via autocrine and paracrine mechanisms (not shown in
figure) (Cabral et al., 2008).
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1.3. Preclinical assays of pain-stimulated and pain-depressed behavior
Traditional preclinical assays of pain typically measure a category of pain-related
behaviors that our lab has called “pain-stimulated behaviors.” Pain-stimulated behaviors
are defined as behaviors (e.g. withdrawal responses) that increase in rate or intensity
following delivery of a noxious stimulus. In assays of pain-stimulated behavior,
antinociception is indicated by decreases in the target behavior. However, decreases in
pain-stimulated behavior can be produced either by a reduction in sensory sensitivity to
the noxious stimulus (i.e. true analgesia) or by nonselective behavioral depressant
effects (e.g. sedation, motor impairment) that limit the subject's ability to respond.
Sedative drugs such as cannabinoid agonists are thus especially prone to produce
false-positive antinociception in assays of pain-stimulated behavior (De Vry et al., 2004;
Finn et al., 2004; Kwilasz and Negus, 2012). In this dissertation, two assays of painstimulated were employed: lactic acid-stimulated stretching and lipopolysaccharide
(LPS)-stimulated mechanical allodynia. In the assay of lactic acid-stimulated stretching,
animals received an IP injection of dilute lactic acid and were immediately observed for
stretching behavior for a 30 min period. A stretch is defined as a contraction of the
abdomen that occurs concurrently with extension of at least one hind limb, and this
behavior increases (pain-stimulated behavior) following delivery of an IP acid injection,
indicative of nociception. In the assay of LPS-stimulated mechanical allodynia, LPS, a
pro-inflammatory constituent of gram-negative bacterial cell walls, is administered as an
IP injection, which has been shown in previous studies to produce mechanical allodynia
(Cahill et al., 1998; Hains et al., 2010). In these studies, mechanical allodynia was
defined as an increased paw-withdrawal response (pain-stimulated behavior) to a series

14
of Von Frey filaments, of graded stiffness, applied to the paw. Clinically effective
analgesics such as ketoprofen and morphine (Flecknell, 2009; Sarzi-Puttini et al., 2010)
have been shown to be effective in assays of pain-stimulated behavior (Pereira Do
Carmo et al., 2009; Kwilasz and Negus, 2012); however, clinically ineffective analgesics
that produce sedation, such as kappa opioid agonists and dopamine receptor
antagonists, also produce false-positive antinociception in assays of pain-stimulated
behavior (Stevenson et al., 2006; Negus et al., 2010b). These data suggest that
preclinical assays of pain-stimulated behavior alone are not sufficient to predict the
efficacy of candidate analgesics.
In contrast to assays of pain-stimulated behavior, “pain-depressed behaviors” are
defined as behaviors such as feeding, locomotion, or operant behavior that decrease in
rate or intensity following delivery of a noxious stimulus. Assays of pain-depressed
behavior have two attributes important to the assessment of candidate analgesics. First,
antinociception is indicated by increases in the target behavior, and as a result, assays
of pain-depressed behavior are not vulnerable to false-positive effects caused by
nonselective behavioral depression (Negus et al., 2010a; Negus et al., 2010b; Kwilasz
and Negus, 2012). Second, assays of pain-depressed behavior may model pain-related
functional impairment and/or depressed mood used to assess pain in both human and
veterinary medicine (Cleeland and Ryan, 1994; Dworkin et al., 2005; National Research
Council, 2011), and thus may provide insight into effects of candidate analgesics on
these clinically relevant components of pain (Negus et al., 2006; Negus et al., 2010a). In
view of these attributes, we have argued that assays of pain-depressed behavior may
complement conventional assays of pain-stimulated behavior and increase the
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predictive validity of preclinical candidate analgesic assessment (Negus et al., 2006;
Negus et al., 2010a). In this dissertation, three assays of pain-depressed behavior were
employed: lactic acid-depressed intracranial self-stimulation (ICSS), lactic aciddepressed feeding, and LPS-depressed ICSS. ICSS is an operant assay in which
subjects respond on a lever to receive pulses of electrical stimulation delivered via
electrodes implanted in the brain’s “reward pathway” (Pereira Do Carmo et al., 2009a;
Negus et al., 2010a; Negus et al., 2010b; Negus et al., 2011). In the assays of acid
depressed ICSS or acid-depressed feeding, an acute IP injection of dilute lactic acid
served as the noxious stimulus to depress both ICSS and feeding behaviors. Similarly,
in the assay of LPS-depressed ICSS, either chronic or acute IP injections of LPS were
administered, which produced depression of ICSS behavior. LPS or pro-inflammatory
cytokine administration has previously been shown to produce inflammation-related
decreases in behavior such as ICSS (Anisman et al., 1996; Anisman et al., 1998;
Borowski et al., 1998; Barr et al., 2003; van Heesch et al., 2013), feeding (Kubera et al.,
2013), and social interaction (Konsman et al., 2008). It was hypothesized that all
cannabinoid drugs tested would produce antinociception in assays of pain-stimulated
behavior, whereas they would lack or show reduced efficacy in assays of paindepressed behavior, especially under conditions in which an acute noxious stimulus
was used (see section 1.5 below).
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1.4. Neurobiology for convergence of ICSS, pain, and cannabinoids
ICSS increases mesolimbic DA. Lateral hypothalamic ICSS (i.e. the type of ICSS
used in the studies of this dissertation) has been shown to stimulate increases in
mesolimbic dopamine (DA) (Neill et al., 2002; Wise, 2005; Cheer et al., 2007). These
ICSS-stimulated increases in mesolimbic DA, most commonly observed in striatal areas
such as the NAc, have been shown to be dependent on release of glutamate from brain
areas such as the LH and septum to the VTA. The VTA is one of the main brain regions
in which cell bodies of dopaminergic afferents are found. Glutamate activates glutamate
receptors on the cell bodies of these dopaminergic neurons, and stimulates the
dopaminergic neurons in the VTA to release DA into the NAc (Shizgal, 1989). DA in the
NAc then stimulates D1 and D2 DA receptors on GABAergic medium spiny neurons in
the NAc, which has been correlated with reward-related events and behaviors, such as
operant drug self-administration, increases in locomotor activity, and ICSS (Neill et al.,
2002; Wise, 2005; Cheer et al., 2007). Similarly, decreases in mesolimbic DA have
been correlated with depressed activity and/or mood as well increased pain
(Neugebauer et al., 2009; Dellagioia et al., 2012; Jarcho et al., 2012).
IP Lactic acid decreases mesolimbic DA. The studies in chapters 2-4 of this
dissertation employ IP lactic acid as a noxious stimulus. Acids such as lactic acid are a
source of protons (i.e. in the form of hydronium ions), which when placed in an aqueous
solution will increase the concentration of protons in that solution. When lactic acid is
administered to the peritoneal cavity of a rat, the concentration of proton ions in the
peritoneal cavity will thus increase. Primary afferent nociceptors present in the
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peritoneal cavity possess receptors for protons such as TRPV1 and acid-sensing ion
channels (ASICs), and are stimulated by activation of these receptors (Holzer, 2011).
Moreover, lactic acid may cause tissue damage, which causes release of proinflammatory molecules such as cytokines, and these molecules can further depolarize
primary afferent nociceptors to transmit pain signals (Rice, 2006). Pro-inflammatory
molecules have also been shown to increase expression of proton-sensitive ion
channels such as TRPV1 on primary afferent nociceptors (Rice, 2006; Holzer and
Holzer-Petsche, 2009), and this phenomenon could also contribute to an enhanced pain
signal following acid administration. The primary pain pathway and its connections to
reward-related regions of the brain are shown in Figure 1.2. In Figure 1.4, the
intersection between the effects of noxious stimulation, ICSS, and cannabinoids on
these reward-related brain regions is illustrated in greater detail. ICSS indirectly
stimulates dopaminergic neurons that project to the NAc via glutamatergic afferents in
the LH and septum; however these dopaminergic neurons are also inhibited by noxious
stimulation in at least two ways. First, peripheral noxious stimulation such as after IP
lactic acid administration activates primary nociceptors and ultimately glutamatergic
projections from the PBN and Amg to GABAergic interneurons in the VTA (Jhou et al.,
2009; Neugebauer et al., 2009; Coizet et al., 2010). These GABAergic interneurons can
then inhibit mesolimbic dopaminergic neurons in the VTA. Second, tissue damage
following IP lactic acid administration can cause release of pro-inflammatory molecules
such as cytokines, and these molecules may further sensitize primary afferents to
produce increased stimulation of pain pathways (Rice, 2006; Holzer and HolzerPetsche, 2009). Pro-inflammatory molecules may also signal at the blood brain barrier
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to cause release of pro-inflammatory molecules and subsequent inflammatory
processes in the brain (Erickson et al., 2012). Brain inflammation, pain, and depression
of mood have also been correlated with decreased mesolimbic DA (Neugebauer et al.,
2009; Dellagioia et al., 2012; Jarcho et al., 2012), although mechanisms underlying
these processes are not fully understood.
CB1/2R agonists increase mesolimbic DA. CB1/2R agonists have been shown to
increase mesolimbic DA (Tanda et al., 1997; Lecca et al., 2006), and thus may be able
to reverse the depression of mesolimbic DA by noxious stimulation. Cannabinoid
receptor agonists have also been shown to activate CB1Rs in the VTA (Fitzgerald et al.,
2012), which are thought to disinhibit dopaminergic cell activity by presynaptically
inhibiting GABAergic interneurons in this region. Moreover, CB1R agonists have been
shown to stimulate VTA dopaminergic cell firing activity (French et al., 1997). CB1Rs
would thus be in a position to inhibit/reverse the excitatory pain signals from the PBN
and Amg to the GABAergic interneurons of the VTA. In addition to the effects of CB1R
agonists on pain signals, CB2R agonists have also been shown to inhibit immune cellrelated functions, such as macrophage- and microglia-activation and migration
(Wilkerson and Milligan, 2011). Inhibition of macrophage activation in the peritoneal
cavity following IP acid administration could decrease further release of proinflammatory molecules that desensitize the primary afferent nociceptor, whereas
inhibition of microglial activation in the spinal cord and brain may also contribute to
decreased pain pathway activation and subsequent decreases in mesolimbic DA (Rice,
2006; Holzer and Holzer-Petsche, 2009).
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Figure 1.4

Figure 1.4. Depiction of the intersection between ICSS, pain, and cannabinoids on
reward-related circuitry. ICSS behavior is dependent on mesolimbic DA and glutamate.
Glutamatergic afferents from regions that include LH and septum (Sep) are stimulated
directly by ICSS and subsequently stimulate dopaminergic cell bodies in the VTA.
Noxious stimulation increases glutamatergic signals at primary afferent nociceptors,
which ultimately project signals to brain regions such as the PBN and Amg. The PBN
and Amg subsequently can stimulate GABAergic interneurons in the VTA to inhibit DA
release in the NAc. Noxious stimulation also stimulates production of pro-inflammatory
molecules (PIM), which can further enhance the sensitivity of nociceptors to noxious
stimulation. CB1R agonists can disinhibit VTA DA neurons by presynaptically inhibiting
GABA release from GABAergic interneurons in the VTA. This property also imbues
CB1R agonists with the potential to block/reverse the inhibition of mesolimbic DA
neurons via noxious stimulation signals from the PBN and Amg. Moreover, CB2R
agonists can inhibit macrophage and microglial cell activation, which reduces release of
pro-inflammatory cytokines in both peripheral and central regions, respectively.
Ultimately, this may lead to a blockade/reversal of pain-induced decreases in
mesolimbic DA.
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1.5. Introduction to data chapters
Chapter 2. Effects of the mixed CB1R/CB2R agonists THC and CP55940
on acute pain-stimulated and pain-depressed behavior. In these studies, intraperitoneal
(IP) injection of dilute acid served as an acute noxious stimulus to stimulate stretching
(a pain-stimulated behavior) and to depress ICSS (a pain-depressed behavior). Initial
experiments indicated that the cannabinoid agonists THC and CP55940 failed to
produce antinociception in the assay of acid-depressed ICSS. Two follow-up studies
were conducted to further evaluate conditions under which THC and/or CP55940 might
be effective. First, previous studies with another drug class (delta opioid agonists)
showed that expression of antinociception in the assay of acid-depressed ICSS could
be obscured by rate-decreasing effects, but that repeated drug treatment could produce
selective tolerance to rate-decreasing effects and unmask antinociception (Negus et al.,
2012). Accordingly, THC effects in assays of acid-stimulated stretching and aciddepressed ICSS were evaluated during chronic THC administration to test the
hypothesis that repeated THC might produce selective tolerance to rate-decreasing
effects and unmask antinociception in the assay of acid-depressed ICSS. Second,
effects of THC and CP55940 were evaluated in an assay of acid-induced depression of
feeding (Stevenson et al., 2006; Kwilasz and Negus, 2012). Feeding is reliably
stimulated by THC and other cannabinoid agonists in the absence of pain (Williams et
al., 1998; Miller et al., 2004; Jarbe and DiPatrizio, 2005; Farrimond et al., 2011),
suggesting that cannabinoids might be more effective in blocking acid-induced
depression of feeding than acid-induced depression of ICSS. The nonsteroidal antiinflammatory drug (NSAID) and clinically effective analgesic ketoprofen (Flecknell,
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2009; Sarzi-Puttini et al., 2010) was tested as a positive control in assays of acidstimulated and acid-depressed behavior. In accordance with the lack of efficacy of
cannabinoid agonists to treat acute pain in clinical studies (Rice, 2006; Karst et al.,
2010; Kraft, 2012), we predicted that THC and CP55940 would be ineffective whereas
ketoprofen would be effective to produce antinociception in assays of pain-depressed
behavior.
Chapter 3. Effects of the FAAH inhibitors URB597 and PF3845
on acute pain-stimulated and pain-depressed behavior. In these studies, we evaluated
the effects of two structurally-unrelated FAAH inhibitors, URB597 and PF3845, in
assays of acute pain-stimulated and pain-depressed behavior. Plasma and brain levels
of the fatty acid ethanolamines AEA, PEA, and OEA were also quantified as biomarkers
for FAAH inhibitor activity. As in the previous chapter, an IP injection of dilute lactic acid
served as the noxious stimulus to stimulate stretching and depress ICSS. Both URB597
and PF3845 have been shown to produce antinociception in several preclinical assays
of pain-stimulated behavior (Ahn et al., 2009; Clapper et al., 2010; Booker et al., 2012;
Ghosh et al., 2012), and furthermore to produce a significantly reduced profile of side
effects compared to direct CB1R agonists (Karst and Wippermann, 2009; Schlosburg et
al., 2009; Alvarez-Jaimes and Palmer, 2011). Due to the reduced side effect profile of
FAAH inhibitors, including reduced sedation, we predicted that FAAH inhibitors might be
more effective than cannabinoid receptor agonists in assays of pain-depressed
behavior.
Chapter 4. Effects of the CB2R agonist GW405833 on acute pain-stimulated and
pain-depressed behavior. In these studies, we assessed the effects of the CB2R
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agonist GW405833 in assays of acute pain-stimulated and pain-depressed behavior. As
in the previous chapters, the noxious stimulus employed in these assays was an acute
IP injection of lactic acid, which either stimulated stretching or depressed ICSS. Due to
their antinociceptive effects in many models of acute and chronic pain and their reduced
side-effect profile versus mixed CB1R/CB2R agonists including reduced sedation
(Malan et al., 2001; Valenzano et al., 2005; Whiteside et al., 2005; Hsieh et al., 2011),
we predicted that a CB2R agonist might also be more effective than mixed CB1R/CB2R
agonists at producing antinociception in an assay of pain-depressed behavior.
Chapter 5. Effects of THC on acute and repeated LPS-induced stimulation of
mechanical allodynia and depression of ICSS. In these studies, repeated or acute
injections of LPS, a pro-inflammatory constituent of gram-negative bacterial cell walls,
were used to model inflammatory-related pain as described previously (Watkins et al.,
1994; Cahill et al., 1998; Hains et al., 2010). Hypersensitivity of withdrawal responses
from mechanical stimuli applied to the hindpaw (mechanical allodynia) served as a
measure of pain-stimulated behavior, and decreases in ICSS served as a measure of
pain-depressed behavior. Both mechanical sensitivity and ICSS were evaluated daily in
each rat during chronic IP LPS treatment. LPS was also administered IP acutely in a
separate experiment. In this study, change in body temperature after acute LPS
administration was also measured as a physiological indicator of LPS effects. THC was
evaluated for its ability to block LPS-induced stimulation of mechanical allodynia and
depression of ICSS. We predicted that both chronic and acute LPS would stimulate
mechanical allodynia and depress ICSS and that acute LPS would increase body
temperature. Given that cannabinoids produce robust anti-inflammatory in preclinical
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studies (Puffenbarger et al., 2000; Croxford and Yamamura, 2005; Pascual et al., 2005;
Valenzano et al., 2005; Whiteside et al., 2005; Cabral et al., 2008; Burstein and Zurier,
2009; Wilkerson and Milligan, 2011), have displayed some efficacy in a clinical trial for
the treatment of the inflammatory disorder rheumatoid arthritis (Blake et al., 2006), and
are clinically indicated in several countries to treat muscle spasticity and related pain
associated with another inflammatory disorder, multiple sclerosis (Leussink et al., 2012),
we predicted that THC would be effective to block LPS-stimulated mechanical allodynia
and LPS-depressed ICSS.
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CHAPTER TWO
Effects of the mixed CB1R/CB2R agonists THC and CP55940
on acute pain-stimulated and pain-depressed behavior.
Published:
Kwilasz, A.J. & Negus S.S. (2012) Dissociable effects of the cannabinoid receptor
agonists Δ9-tetrahydrocannabinol and CP55940 on pain-stimulated versus paindepressed behavior in rats, The Journal of Pharmacology and Experimental
Therapeutics, 343(2): 389-400.

2.1. Introduction
Marijuana has been used for centuries to treat pain, and THC, the primary active
constituent of marijuana, as well as other cannabinoid agonists such as CP55940
produce antinociception in nearly all preclinical assays of pain (Rice, 2006; Karst et al.,
2010). Despite the robust antinociceptive effects of cannabinoid agonists in preclinical
assays of pain in animals, in well-controlled clinical trials in humans, cannabinoid
agonists do not produce analgesia against acute pain and have weak efficacy with a
narrow therapeutic window against chronic pain (Raft et al., 1977; Rice, 2006; Karst et
al., 2010; Kraft, 2012). This disparity between preclinical and clinical findings suggest
that traditional preclinical assays of pain used to study cannabinoids in animals may not
be sufficient to predict clinical analgesic effects in humans.
Traditional preclinical assays used to measure pain can be classified as assays
of pain-stimulated behavior. In assays of pain-stimulated behavior, delivery of a noxious
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stimulus increases the rate, frequency, or intensity of the target behavior (e.g.
withdrawal response), and antinociception is indicated by drug-induced decreases in the
target behavior. However, drug-induced decreases may be the result of either
nonspecific behavioral depression (i.e. sedation/motor suppression) or a decreased
sensitivity to the noxious stimulus (i.e. analgesia). Cannabinoid agonists such as THC
and CP55940 and other drugs that produce behavioral depression are thus prone to
producing false-positive antinociception in assays of pain-stimulated behavior (De Vry et
al., 2004; Finn et al., 2004; Kwilasz and Negus, 2012). In contrast, in assays of paindepressed behavior, delivery of a noxious stimulus decreases the rate, frequency, or
intensity of the target behavior, and antinociception is indicated by drug-induced
increases in the target behavior. Behavioral depressants thus do not produce falsepositive antinociception in assays of pain-depressed behavior (Negus et al., 2010a;
Negus et al., 2010b; Kwilasz and Negus, 2012). Furthermore, pain-depressed behavior
may model clinically relevant dimensions of pain, such as functional impairment and/or
depressed mood, that are often used to diagnose pain in both human and veterinary
medicine (Cleeland and Ryan, 1994; Dworkin et al., 2005; National_Research_Council,
2011).
The goal of the present study was to assess the effects of THC and CP55940 in
assays of acute pain-stimulated and pain-depressed behavior. THC and CP55940 were
tested in assays of lactic acid-stimulated stretching, lactic acid-depressed ICSS, and
lactic acid-depressed feeding. The nonsteroidal anti-inflammatory drug and clinically
effective analgesic ketoprofen (Flecknell, 2009; Sarzi-Puttini et al., 2010) was also
included as a positive control.
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2.2. Methods
Subjects
Seventy-nine male Sprague-Dawley rats (Harlan, Frederick, MD, USA) weighing
approximately 300-320 g (age 10-11 weeks) at the time of surgery and/or delivery were
individually housed and maintained on a 12 h light/dark cycle with lights on from 6:00
a.m. to 6:00 p.m. Rats had free access to food and water except during testing. Animal
maintenance and research were in compliance with National Institutes of Health
guidelines on care and use of animal subjects in research and adhered to guidelines of
the Committee for Research (National Research Council, 2011). All animal use
protocols were approved by the Virginia Commonwealth University Institutional Animal
Care and Use Committee.

Assay of lactic acid-stimulated stretching
Behavioral procedure. Twenty-six rats that failed to meet the criteria for ICSS
within 4 weeks (see below) were used for studies of lactic acid-stimulated stretching as
described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013). During test
sessions, rats were placed into an acrylic test chamber (31.0 x 20.1 x 20.0 cm) for a 30
min observation period that began immediately after injection of dilute lactic acid (1.8%
in a volume of 1 ml/kg). A stretch was operationally defined as a contraction of the
abdomen followed by a stretching of at least one hind limb, and the number of stretches
during the observation period was counted.
Studies with acute THC were conducted in four phases. First, a THC dose-effect
curve was determined by administering THC (0.32-10 mg/kg or vehicle) 30 min prior to
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acid. Doses were delivered in a Latin-square dose order across rats and separated by
at least one week. Second, the time course of effects produced by 3.2 mg/kg THC was
determined by varying the interval between administration of THC and acid (10, 30, 100,
300 min, and 24 h). A dose of 3.2 mg/kg THC was chosen for time course studies
because it was the lowest dose to significantly decrease acid-stimulated stretching
during dose-effect testing. Each pretreatment time was tested in a different test session
in randomized order, and test sessions were separated by at least one week. Third, to
assess the role of cannabinoid 1 receptors in mediating THC effects, THC-induced
antinociception was evaluated for its sensitivity to antagonism by the cannabinoid 1
receptor antagonist rimonabant. For these studies, rimonabant (0.01-1.0 mg/kg or
vehicle) was administered 20 min prior to THC (3.2 mg/kg), and acid was administered
30 min after THC. All THC and rimonabant doses were delivered in a Latin-square dose
order across rats and separated by at least one week.
Finally, to assess the potential for antinociceptive tolerance to repeated THC,
acid-stimulated stretching was evaluated following chronic treatment with THC (3.2
mg/kg/day). Initially a vehicle test was conducted in which rats were administered THC
vehicle prior to treatment with acid. Beginning one week later, THC (3.2 mg/kg) was
administered once daily for 22 days. On days 1, 8, 15 and 22, acid (1.8% in 1 ml/kg)
was administered 30 min after THC, and the stretching response was evaluated. Effects
of 3.2 mg/kg THC on acid-stimulated stretching were redetermined one additional time
two weeks after termination of chronic THC.
To provide a comparison for results with THC, two additional groups of rats were
used to evaluate the high-efficacy cannabinoid 1 receptor agonist CP55940 (0.0032-0.1
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mg/kg or vehicle) and the NSAID ketoprofen (1 mg/kg or saline). In both cases, the test
drug was administered 30 min prior to acid, and tests were separated by one week.
Data Analysis. Drug effects on acid-stimulated stretching were evaluated by
repeated measures one-way analysis of variance (ANOVA) or t test as appropriate. A
significant ANOVA was followed by Newman Keul’s or Dunnett’s post hoc test, and the
criterion for significance was set at p < 0.05.

Assay of intracranial self-stimulation (ICSS)
Surgery. All rats were anesthetized with isoflurane (2.5-3% in oxygen; Webster
Veterinary, Phoenix, AZ, USA) for implantation of stainless steel electrodes (Plastics
One, Roanoke, VA, USA). One pole (the cathode) of each bipolar electrode was 0.25
mm in diameter and covered with polyamide insulation except at the flattened tip,
whereas the other pole (the anode) was 0.125 mm in diameter and uninsulated. The
cathode was implanted in the left medial forebrain bundle at the level of the lateral
hypothalamus (2.8 mm posterior to bregma, 1.7 mm lateral from the midsagittal suture,
and 8.8 mm below the skull). The anode was wrapped around one of the three skull
screws to serve as the ground, and the skull screws and electrode assembly were
secured to the skull with orthodontic resin. The animals were allowed to recover for at
least 7 days prior to commencing ICSS training.
Apparatus. Experiments were conducted in sound-attenuating boxes that
contained modular acrylic test chambers (29.2 x 30.5 x 24.1 cm) equipped with a
response lever (4.5 cm wide, extended 2 cm through the center of one wall, 3 cm off the
floor), stimulation lights (three lights colored red, yellow, and green, positioned 7.6 cm
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directly above the response lever), a 2 W house light, and an ICSS stimulator (Med
Associates, St. Albans, VT, USA). Electrodes were connected to the stimulator via a
swivel connector (Model SL2C, Plastics One, Roanoke, VA, USA). The stimulator was
controlled by computer software that also controlled programming parameters and data
collection (Med Associates, St. Albans, VT, USA).
Behavioral procedure. After initial shaping of lever press responding, rats were
trained under a continuous reinforcement schedule of brain stimulation using
procedures similar to those described previously (Kwilasz and Negus, 2012; Rosenberg
et al., 2013). During sessions lasting 30-60 min, each lever press resulted in the
delivery of a 0.5 s train of square wave cathodal pulses (0.1 ms pulse duration), and
stimulation was accompanied by illumination of the stimulus lights over the lever.
Responses during the 0.5 s stimulation period did not earn an additional stimulation.
Initially, the frequency of stimulation was held constant at 158 Hz, and the stimulation
intensity for each rat was adjusted gradually to the lowest value that would sustain a
high rate of reinforcement (> 30 stimulations/min). This intensity (100-280 µA across
rats) was then held constant for the remainder of the study, and frequency
manipulations were introduced. Sessions involving frequency manipulations consisted
of sequential 10 min components. During each component, a descending series of 10
current frequencies (158 to 56 Hz in 0.05 log increments) was presented, with each
frequency available during sequential 1 min frequency trials. Each frequency trial began
with a 10 s time out, during which responding had no scheduled consequences. During
the last 5 s of this time out, five noncontingent “priming” stimulations were delivered at
the frequency available during that trial, and the lever lights were illuminated during

30
each stimulation. Noncontingent stimulations were separated by intervals of 0.5 s. This
noncontingent stimulation was then followed by a 50 s “response” phase, during which
responding produced electrical stimulation under the continuous reinforcement
schedule. Training continued with presentation of three to six sequential components
per day until rats reliably responded for only the first four to six frequency trials of all
components for at least three consecutive days. In general, rats were implanted with
electrodes and trained on ICSS procedures in groups of 10-12. The first six rats in each
group to meet training criteria were then advanced to testing, while the remaining rats
were assigned to assays of acid-stimulated stretching as described above.
Once training was completed, testing was initiated. The first component of each
test session was considered to be an acclimation component, and data from this
component were discarded. Data from the second and third “baseline” components
were used to calculate baseline parameters of the frequency-rate curves for that
session (see “Data Analysis”). Drugs were administered immediately after removing the
subjects from the operant chamber after the third baseline component. Studies of THC
effects on ICSS were conducted in four phases. In the first phase, the effects of acute
THC on ICSS were studied in two separate groups of rats. In the first group of rats, THC
effects on ICSS were studied in the absence of the noxious stimulus (control ICSS).
Subjects were placed in their home cages after administration of THC (0.32-10 mg/kg or
vehicle) and then transferred back to the operant chambers at designated times (30,
100, 180, 300 min) for two consecutive “test” components, totaling 20 min at each time
point. In the second group of rats, THC effects on ICSS were studied in the presence of
the noxious stimulus (acid-depressed ICSS). Subjects were administered THC (0.32-3.2
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mg/kg or vehicle) 30 min prior to lactic acid (1.8% in a volume of 1 ml/kg), which was
administered immediately before two consecutive “test” components. THC and acid
doses were administered in Latin-square order and were separated by at least one
week. The second phase examined the effects of 3.2 mg/kg THC administered 180 and
300 min before acid treatment. These times were selected because initial results
indicated that treatment with 3.2 mg/kg THC significantly decreased acid-stimulated
stretching after 180 and 300 min but did not significantly decrease ICSS at these
pretreatment times in the absence of a noxious stimulus. For these experiments,
subjects were placed in their home cages after THC administration and then injected
with acid and transferred back to the operant chamber at the designated time (180 or
300 min) for two consecutive “test” components. Each pretreatment time/dose
combination was tested in a different test session in randomized order, and test
sessions were separated by at least one week. In the third phase, the ability of
rimonabant to block THC effects on ICSS was investigated. In these experiments,
rimonabant (1 mg/kg or vehicle) was administered 50 min prior to testing and 20 min
before THC (3.2 mg/kg or vehicle). THC and rimonabant doses were administered in
Latin-square order and were separated by at least one week. In phases 1-3, training
and test sessions were conducted Monday-Friday for the duration of the experiment,
with test sessions conducted on Thursdays or Fridays.
The final phase of studies with THC examined effects of chronic THC in two
separate groups of rats. In the first group, the effects of chronic THC were studied in the
absence of the acid noxious stimulus (control ICSS). For these experiments, subjects
initially received chronic treatment of THC vehicle (1 ml/kg/day) for three weeks while
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being tested with THC (1-10 mg/kg or vehicle) once/week in a Latin-Square dose order.
Following this treatment regimen, subjects were treated for 11 days with 1 mg/kg/day
THC, 11 days with 3.2 mg/kg/day THC, and lastly 11 days with 10 mg/kg/day THC (i.e.
33 days of total THC treatment). On the last four days of treatment with each dose of
chronic THC, subjects were tested with THC (1-10 mg/kg or vehicle) one dose/day in a
Latin-Square dose order. Subjects that received test THC doses lower than the chronic
THC dose for that day were administered the difference of the test and chronic doses at
the end of the test session. In the second group of rats, the effects of chronic THC were
studied in the presence of the noxious stimulus (acid-depressed ICSS). For these
experiments, THC vehicle was initially administered prior to acid vehicle. One week
later, THC vehicle was administered prior to acid. Beginning one week later, THC (3.2
mg/kg) was administered once daily for 22 days. On days 1, 8, 15, and 22, acid (1.8% in
1 ml/kg) was administered 30 min after THC, and ICSS was evaluated as described
above. Effects of 3.2 mg/kg THC on acid-depressed ICSS were redetermined one
additional time two weeks after termination of chronic THC. In both groups of rats,
training and test sessions were conducted seven days/week.
In addition to these studies with THC, two additional groups of rats were tested
with either CP55940 or ketoprofen. For these studies, one group was treated with
CP55940 (0.01-0.32 mg/kg or vehicle) and the other with ketoprofen (1 mg/kg or saline)
30 min before treatment with 1.8% lactic acid or lactic acid vehicle (sterile water).
Training and test sessions were conducted Monday-Friday for the duration of the
experiment, with test sessions conducted on Thursdays or Fridays.
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Data Analysis. The primary dependent variable in this ICSS procedure was the
reinforcement rate in stimulations per minute during each frequency trial. To normalize
these data, raw reinforcement rates from each trial in each rat were converted to
percent maximum control rate (%MCR), with the MCR defined as the mean of the
maximal rates observed during the second and third “baseline” components for that
session in that rat. Thus, %MCR values for each trial were calculated as (Reinforcement
Rate During a Frequency Trial ÷ Maximum Control Rate) x 100. For each test session,
data from the second and third components were averaged to yield a baseline
frequency-rate curve. Data from each test (two consecutive “test” components) were
averaged for each test for each rat. Baseline and test curves were then averaged
across rats to yield mean baseline and test curves for each manipulation. For statistical
analysis, results were compared by repeated measures two-way ANOVA, with
treatment and ICSS frequency as the two factors. A significant ANOVA was followed by
Holm-Sidak post hoc test, and the criterion for significance was set at p < 0.05.
To provide an additional summary of ICSS performance, the total number of
stimulations per component was calculated as the sum of stimulations delivered across
all 10 frequency-trials of each component. Test data were then normalized to individual
baseline data using the equation Percent Baseline Total Stimulations per Component =
(Mean Total Stimulations per Test Component ÷ Mean Total Stimulations per Baseline
Component) x 100. Data were then averaged across rats in each experimental condition
and compared by repeated measures one-way ANOVA or two-way ANOVA where
appropriate. A significant one-way ANOVA was followed by Newman Keul’s or
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Dunnett’s post hoc test, a significant two-way ANOVA was followed by Holm-Sidak post
hoc test, and the criterion for significance was set at p < 0.05.

Assay of lactic acid- and prefeeding-depressed feeding
Behavioral procedure. Sixteen rats were used for feeding studies. During test
sessions, rats were placed into an acrylic test chamber (31 x 20.1 x 20 cm) within a
sound- and light-attenuating cabinet for a 30 min feeding session. Rodent 45 mg
purified food pellets (Product #F0021, Bio-Serv, Frenchtown, NJ) were delivered in preweighed glass petri dishes (60 x 15 mm) (Corning Life Sciences, Pittston, PA) securely
taped to the bottom left corner of the test chamber. Spilled pellets/dust were collected at
the end of the session and added back to the petri dish, which was then re-weighed.
Percent Body Weight Food Consumed after each session was determined with the
following equation: [(Pre-Session Dish Weight – Post-Session Dish Weight) ÷ [Daily
Subject’s Weight (g)] x 100]. Initial baseline feeding sessions were conducted for two
weeks weeks until stable feeding baselines were achieved. Studies were conducted in
four phases. First, pain-related depression of feeding was established by administering
dilute lactic acid (0.56-1.8% or vehicle in a volume of 1 ml/kg) immediately before the
test session. For these studies, drug vehicle was also administered 30 min before acid.
Second, THC and ketoprofen effects on pain-related depression of feeding were
determined by administering THC (0.32-3.2 mg/kg or vehicle) or ketoprofen (1 mg/kg or
vehicle) 30 min prior to injection of lactic acid (1.8% or vehicle in a volume of 1 ml/kg),
which was administered immediately before the test session. Third, satiation-related
depression of feeding was established by exposing rats to a 60 min prefeeding session
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30 min prior to the test session. Prefeeding sessions were similar to test sessions,
except that they were conducted in separate chambers not housed in sound- and lightattenuated cabinets. Finally, THC and ketoprofen effects on satiation-related depression
of feeding were determined by administering THC (0.1-1 mg/kg or vehicle) or ketoprofen
(1 mg/kg or vehicle) immediately after a 60 min prefeeding session and 30 min prior to
the test session. THC doses were delivered in a Latin-square dose order across rats
and separated by at least one week. Ketoprofen was tested after THC. Rats were
housed in their homecages with free access to food and water at all times except during
feeding sessions.
In addition to these studies with THC and ketoprofen, an additional group of rats
was tested with CP55940 under conditions of acid- and satiation-related depression of
feeding. In this study, animals were treated with CP55940 (0.0032-0.032 mg/kg or
vehicle) 30 min before the feeding session using procedures identical to those with THC
and ketoprofen. In all feeding studies, rats were housed in their homecages with free
access to food and water at all times except during feeding sessions. Training and test
sessions were conducted Monday-Friday, with test sessions conducted on Wednesdays
or Fridays.
Data Analysis. Drug effects on acid- and satiation-related depression of feeding
were evaluated by repeated measures one-way ANOVA. A significant ANOVA was
followed by Newman Keul’s or Dunnett’s post hoc test, and the criterion for significance
was set at p < 0.05.
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Drugs
Lactic acid was purchased from Sigma Chemical Co. (St. Louis, MO). THC,
CP55940, and rimonabant were provided by the National Institute on Drug Abuse Drug
Supply Program (Bethesda, MD). Ketoprofen was purchased from Spectrum Chemical
Co. (New Brunswick, NJ). Lactic acid was prepared in sterile water. THC, CP55940,
and rimonabant were prepared in a vehicle consisting of ethanol, emulphor EL-620
(Rhone-Poulenc; Princeton, NJ), and sterile saline in a ratio of 1:1:18, respectively.
Ketoprofen was prepared in sterile saline except in feeding tests, in which it was
prepared in the same vehicle as THC. All solutions were injected intraperitoneally in a
volume of 1 ml/kg.

2.3. Results
Effects of THC on acid-stimulated stretching. Figure 2.1 shows that THC
produced dose-dependent, time-dependent, and rimonabant-reversible antinociception
in the assay of acid-stimulated stretching. IP administration of acid (1.8% lactic acid in a
volume of 1 ml/kg) stimulated approximately 30 stretches after administration of THC
vehicle (gray bars in all panels). Figure 2.1a shows that stretching was significantly
lower 30 min after administration of 3.2 and 10 mg/kg THC than after THC vehicle.
Figure 2.1b shows that 3.2 mg/kg THC produced a significant reduction in acidstimulated stretching from 10-300 min with recovery after 24 h. Figure 2.1c shows that
rimonabant dose-dependently blocked the antinociceptive effect of 3.2 mg/kg THC, and
significant antagonism was achieved at a dose of 1.0 mg/kg rimonabant.
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Effects of THC on ICSS in the absence of a noxious stimulus. Figure 2.2
shows that THC produced a dose-dependent, time-dependent, and rimonabantreversible decrease in ICSS in the absence a noxious stimulus. During each test
session, a “baseline” frequency-rate curve was determined before testing to permit
determination of the Maximum Control Rate (MCR) for that session. Over the course of
the entire study this group of rats, the average MCR was 59.7 ± 2.6 stimulations/trial
and the average baseline total stimulations was 266.6 ± 56.8. Reinforcement rates
during each frequency trial of a session were then expressed as a percentage of that
session’s MCR, and the average baseline frequency-rate curve for studies with THC is
shown in Figure 2.2a as a gray line. Rats generally did not respond at frequencies of
56-89 Hz, and reinforcement rates increased across a frequency range of 89-158 Hz.
Maximum reinforcement rates were usually observed at the highest stimulation
frequencies. When administered 30 min prior to an ICSS session, THC produced a
dose-dependent rightward and downward shift in the ICSS frequency-rate curve (Fig.
2.2a). Low doses of 0.32 and 1 mg/kg THC had no effect on control ICSS in the
absence of the acid noxious stimulus; however, treatment with 3.2 mg/kg THC
significantly decreased reinforcement rates at a single frequency of 89 Hz, and
treatment with 10 mg/kg THC significantly decreased reinforcement rates at frequencies
of 89-158 Hz compared to treatment with THC vehicle. THC also produced a dosedependent and time-dependent decrease in total stimulations (Fig. 2.2b). Low doses of
0.32 and 1 mg/kg THC had no effect on total stimulations at any time point, but 3.2
mg/kg THC significantly decreased total stimulations at a pretreatment time of 30 min,
and 10 mg/kg THC significantly decreased total stimulations at pretreatment times of
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30-180 min. THC-induced decreases in ICSS were also blocked by pretreatment with
rimonabant (Fig. 2.2c). Rimonabant (1 mg/kg) administered 50 min before testing had
no effect on ICSS alone, but significantly blocked decreases in ICSS induced by 30 min
pretreatment with 3.2 mg/kg THC.
Effects of THC on acid-induced depression of ICSS. Figure 2.3 shows that
the same noxious stimulus used in the stretching assay (IP injection of 1.8% lactic acid
in 1 ml/kg) depressed ICSS. Treatment with acid vehicle had little effect on the
frequency-rate curve; however, treatment with 1.8% lactic acid depressed ICSS,
producing a significant rightward shift in the frequency-rate curve and a decrease in
total stimulations delivered across all frequencies. Figure 2.4 shows that THC failed to
produce antinociception in the assay of acid-depressed ICSS. Rather, when
administered 30 min before acid treatment, THC produced a further, dose-dependent
depression of ICSS. Low doses of 0.32 and 1 mg/kg THC significantly decreased ICSS
at a single frequency of 141 Hz, and treatment with 3.2 mg/kg THC significantly
decreased ICSS at frequencies of 126, 141, and 158 Hz compared to treatment with
THC vehicle (Fig. 2.4a). Additionally, treatment with THC (0.32-3.2 mg/kg) or its vehicle
30 min before acid administration significantly decreased total stimulations delivered
across all frequencies, and there was a trend for treatment with THC to exacerbate
acid-induced decreases in total stimulations, but this trend did not achieve statistical
significance (Fig. 2.4b). A dose of 3.2 mg/kg THC also failed to block acid-induced
depression of ICSS when it was administered 180 or 300 min before acid treatment
(Fig. 2.4c). These were times at which this dose of THC significantly decreased acid-
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stimulated stretching (Fig. 2.1b) but did not significantly decrease ICSS in the absence
of a noxious stimulus (Fig. 2.2b).
Effects of CP55940 and ketoprofen on acid-stimulated stretching and on
ICSS in the absence or presence of acid. Figure 2.5a-b shows that CP55940, like
THC, produced antinociception in the assay of acid-stimulated stretching but not in the
assay of acid-depressed ICSS. However, unlike THC, CP55940 was approximately 10fold more potent to produce antinociception in the assay of acid-stimulated stretching
than to decrease control ICSS in the absence of the acid stimulus. In particular, doses
of 0.01 and 0.032 mg/kg CP55940 produced significant antinociception in the assay of
acid-stimulated stretching (Fig. 2.5a) while 10-fold higher doses of 0.1-0.32 mg/kg were
required to decrease control ICSS (Fig. 2.5b, open bars). Despite this evidence for
selective antinociception, CP55940 still failed to block acid-induced depression of ICSS.
Rather, CP55940 only exacerbated acid-induced depression of ICSS (Fig. 2.5b, closed
bars) at the same doses of 0.1 and 0.32 mg/kg that decreased control ICSS (Fig. 2.5a,
open bars). Figure 2.5c-d shows that, in contrast to THC and CP55940, the NSAID
ketoprofen produced antinociception in assays of both acid-stimulated stretching and
acid-depressed ICSS. Thus, a dose of 1.0 mg/kg ketoprofen significantly reduced acidstimulated stretching (Fig. 2.5c). The same dose of 1.0 mg/kg ketoprofen had no effect
on control ICSS, but significantly blocked acid-induced depression of ICSS (Fig. 2.5d).
Effects of chronic THC treatment on acid-stimulated stretching and on
ICSS in the absence or presence of acid. Chronic THC treatment produced a dosedependent tolerance to THC-induced rate-decreasing effects on control ICSS.
Specifically, complete tolerance was observed to the rate-decreasing effects of 3.2
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mg/kg THC following chronic treatment with 3.2 and 10 mg/kg/day THC but not
following 1 mg/kg/day THC (Fig. 2.6). In the assay of acid-stimulated stretching, chronic
THC treatment (3.2 mg/kg/day) produced duration-dependent partial tolerance to THCinduced antinociceptive effects. Partial tolerance to THC-induced antinociceptive effects
was observed on day 15 of chronic THC treatment (Fig. 2.7a). No greater tolerance was
produced by an additional 7 days of treatment, and full THC antinociception recovered 2
weeks after termination of chronic THC. In contrast, chronic THC treatment (3.2
mg/kg/day) did not produce antinociception in the assay of acid-depressed ICSS (Fig.
2.7b) at treatment durations that produced significant antinociception in the assay of
acid-stimulated stretching (Fig. 2.7a) and complete tolerance to THC-induced ratedecreasing effects on control ICSS (Fig. 2.6). Analysis of frequency-rate curves (data
not shown) indicated that THC initially exacerbated acid-induced depression of ICSS on
days 1 and 8 of chronic THC treatment, and that tolerance to this effect developed by
days 15 and 22 of chronic THC treatment. No greater tolerance was produced by an
additional 7 days of treatment, and THC exacerbation of acid-induced depression of
ICSS recovered 2 weeks after termination of chronic THC.
Effects of THC, ketoprofen, and CP55940 on feeding depressed by acid or
prefeeding. Lactic acid produced a concentration-dependent decrease in food
consumption, and exposing rats to a 60 min prefeeding session before testing also
significantly decreased food consumption by approximately the same extent as 1.8%
lactic acid (Fig. 2.8a). Neither THC nor ketoprofen significantly altered food
consumption in the absence of acid or prefeeding (Fig. 2.8b). Ketoprofen but not THC
significantly blocked acid-induced depression of feeding (Fig. 2.8c), and in contrast,
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THC but not ketoprofen significantly attenuated prefeeding-induced depression of
feeding (Fig. 2.8d). CP55940 did not produce significant effects on acid- (Fig. 2.8e) or
prefeeding- (Fig. 2.8f) induced depression of feeding, although an intermediate dose of
0.01 mg/kg CP55940 did more than double mean food consumption after prefeeding.
Higher CP55940 doses were not tested in the feeding assays because they significantly
decreased both control and acid-depressed ICSS (Fig. 2.5b).
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Figure 2.1

Figure 2.1. Δ9-tetrahydrocannabinol (THC) produced dose-dependent, timedependent, and rimonabant-reversible blockade of lactic acid-stimulated stretching. The
left panel (a) shows effects of THC (0.1-10 mg/kg) or its vehicle administered 30 min
before acid treatment. Abscissa: dose THC in milligrams per kilogram. Ordinates (all
panels): number of stretches observed during a 30 min observation period. The center
panel (b) shows effects of THC (3.2 mg/kg) administered 10 min-24 h before acid
treatment. Effects of vehicle administered 30 min before acid treatment are included for
comparison. Abscissa: time following THC or vehicle administration. The right panel (c)
shows the effects of 50 min pretreatment with rimonabant (0.01-1.0 mg/kg) or its vehicle
and 30 min pretreatment with THC (3.2 mg/kg) before acid treatment. Effects of
rimonabant vehicle + THC vehicle + acid are included for comparison. Abscissa: dose
rimonabant in milligrams per kilogram. One-way ANOVA indicated significant main
effects of THC treatment in panel a [F(5,25)=6.63; p<0.001], time in panel b
[F(5,25)=7.65; p<0.001], and rimonabant dose in panel c [F(4,20)=11.21; p<0.001].
Asterisks (*) indicate significantly different from vehicle + acid in all panels or dollar
signs ($) indicate significantly different from 30 min pretreatment with THC (3.2 mg/kg)
in panel b and from THC (3.2 mg/kg) + rimonabant vehicle in panel c as determined by
Newman-Keuls post hoc test, p < 0.05. All bars show mean ± SEM in six rats.
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Figure 2.2

Figure 2.2. Δ9-tetrahydrocannabinol (THC) produced dose-dependent, timedependent, and rimonabant-reversible depression of intracranial self-stimulation (ICSS)
in the absence of a noxious stimulus. The left panel (a) shows ICSS frequency-rate
curves determined 30 min after treatment with THC (0.32-10 mg/kg) or its vehicle.
Abscissa: frequency of electrical brain stimulation in hertz (log scale). Ordinate: percent
maximum control response rate (%MCR). The average baseline ICSS frequency-rate
curve for the entire study in this group of rats is shown by the gray line for comparison,
but these data were not included in statistical analysis. Two-way ANOVA indicated a
significant main effect of THC treatment [F(4,20)=11.78; p<0.001], a significant main
effect of frequency [F(9,45)=19.31; p<0.001], and a significant frequency × treatment
interaction [F(36,180)=4.77; p<0.001]. Filled symbols indicate frequencies at which
reinforcement rates after THC treatment were significantly lower than rates after THC
vehicle treatment as determined by Holm-Sidak post hoc test, p < 0.05. All data show
mean ± SEM in six rats. The center panel (b) shows the total number of stimulations per
component expressed as a percent of baseline stimulations per component following
treatment with THC (0.32-10.0 mg/kg) or its vehicle at various pretreatment times.
Abscissa: time following THC or vehicle administration. Ordinate: percent baseline total
number of stimulations per component. Two-way ANOVA indicated a significant main
effect of THC treatment [F(4,20)=12.35; p<0.001] and a significant treatment × time
interaction [F(12,60)=5.93; p<0.001]. Filled symbols indicate significantly lower than
vehicle treatment at indicated time as determined by Holm-Sidak post hoc test, p < 0.05.
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All data show mean ± SEM in six rats. The right panel (c) shows the total number of
stimulations per component expressed as a percent of baseline stimulations per
component following 50 min pretreatment with rimonabant (1 mg/kg) or its vehicle and
30 min pretreatment with THC (3.2 mg/kg) or its vehicle. Abscissa: dose rimonabant in
milligrams per kilogram. Ordinate: percent baseline total number of stimulations per
component. One-way ANOVA indicated a significant main effect of treatment
[F(3,12)=17.04; p<0.001]. The asterisk (*) indicates significantly different from
rimonabant vehicle + THC vehicle and dollar signs ($) indicate significantly different
from rimonabant vehicle + THC (3.2 mg/kg) as determined by Newman-Keuls post hoc
test, p < 0.05. All bars show mean ± SEM in five rats.
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Figure 2.3

Figure 2.3. Lactic acid depresses intracranial self-stimulation (ICSS). The left panel (a)
shows ICSS frequency-rate curves determined after treatment with THC vehicle 30 min
before lactic acid vehicle or 1.8% lactic acid administration. Abscissa: frequency of
electrical brain stimulation in hertz (log scale). Ordinate: percent maximum control
response rate (%MCR). The average baseline ICSS frequency-rate curve for the entire
study in this group of rats is shown by the gray line for comparison, but these data were
not included in statistical analysis. Two-way ANOVA indicated a significant main effect
of frequency [F(9,36)=23.92; p<0.001] and a significant frequency × treatment
interaction [F(9,36)=2.40; p=0.030]. Filled symbols indicate frequencies at which
reinforcement rates after acid treatment were significantly lower than rates after acid
vehicle treatment as determined by Holm-Sidak post hoc test, p < 0.05. The right panel
(b) shows the total number of stimulations per component expressed as a percent of
baseline stimulations per component determined after treatment with THC vehicle 30
min before lactic acid vehicle or 1.8% lactic acid administration. Abscissa: Lactic acid
concentration. Ordinate: percent baseline total number of stimulations per component.
The asterisk (*) indicates 1.8% lactic acid significantly depressed ICSS compared to 0%
lactic acid (i.e. lactic acid vehicle) as determined by paired t test [t(4)=6.95; p=0.002].
All bars show mean ± SEM in five rats.
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Figure 2.4

Figure 2.4. Δ9-tetrahydrocannabinol (THC) exacerbates lactic acid-induced depression
of intracranial self-stimulation (ICSS). The left panel (a) shows ICSS frequency-rate
curves determined after treatment with THC (0.32-3.2 mg/kg) or its vehicle 30 min
before acid administration. Abscissa: frequency of electrical brain stimulation in hertz
(log scale). Ordinate: percent maximum control response rate (%MCR). The THC
vehicle + acid vehicle frequency-rate curve is shown by the gray line for comparison, but
these data were not included in statistical analysis. Two-way ANOVA indicated a
significant main effect of THC treatment [F(3,12)=5.16; p=0.016], a significant main
effect of frequency [F(9,36)=6.68; p<0.001], and a significant frequency × treatment
interaction [F(27,108)=4.62; p<0.001]. Filled symbols indicate frequencies at which
reinforcement rates after THC + acid treatment were significantly lower than after
vehicle + acid treatment as determined by Holm-Sidak post hoc test, p < 0.05. All data
show mean ± SEM in five rats. The center panel (b) shows the total number of
stimulations per component expressed as a percent of baseline stimulations per
component after treatment with THC (0.32-3.2 mg/kg) or its vehicle 30 min before acid
administration. Abscissa: dose THC in milligrams per kilogram. Ordinate: percent
baseline total number of stimulations per component. One-way ANOVA indicated a
significant main effect of treatment [F(4,16)=19.26; p<0.001]. The asterisks (*) indicate
treatment with THC vehicle + acid or THC + acid significantly depressed ICSS
compared to treatment with THC vehicle + acid vehicle as determined by Newman
Keul’s post hoc test, p < 0.05. All bars show mean ± SEM in five rats. The right panel (c)
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shows the total number of stimulations per component expressed as a percent of
baseline stimulations per component following treatment with THC vehicle 30 min
before acid vehicle or acid administration, or THC (3.2 mg/kg) 30-300 min before acid
administration. Abscissa: time following THC or vehicle administration. Ordinate:
percent baseline total number of stimulations per component. One-way ANOVA
indicated a significant main effect of treatment [F(4,12)=14.43; p<0.001]. The asterisks
(*) indicate treatment with THC vehicle + acid or THC (3.2 mg/kg) + acid significantly
depressed ICSS compared to treatment with THC vehicle + acid vehicle as determined
by Newman Keul’s post hoc test, p < 0.05. All bars show mean ± SEM in four rats.

48
Figure 2.5

Figure 2.5. Effects of CP55940 (top panels) and ketoprofen (bottom panels) on lactic
acid-stimulated stretching and lactic acid-induced depression of intracranial selfstimulation (ICSS). Abscissae (all panels): drug dose in mg/kg. Left ordinates: number
of stretches observed during 30 min observation periods. Right ordinates: percent
baseline total number of stimulations per component. CP55940 dose-dependently
blocked acid-stimulated stretching (panel a, [F(4,16)=38.80; p<0.001]) as indicated by
one-way ANOVA. Two-way ANOVA on ICSS data in the presence and absence of acid
treatment indicated a significant main effect of CP55940 dose [F(4,16)=34.44; p<0.01],
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a significant main effect of acid treatment ([F(1,4)=15.69; p=0.017], but no significant
interaction (panel b). Ketoprofen blocked acid-induced stimulation of stretching (panel c,
[t(3)=4.43; p=0.021]) as indicated by t-test. Two-way ANOVA on ICSS data in the
presence and absence of acid treatment indicated a significant main effect of ketoprofen
dose ([F(1,3)=16.95 p=0.026], a significant main effect of acid treatment ([F(1,3)=13.71
p=0.034], but no significant interaction (panel d). In panels a and c, asterisks (*) indicate
significant difference from a “0” drug dose (i.e. vehicle) + lactic acid as determined by
one-way ANOVA followed by Dunnett’s post hoc test (CP55940) or by t-test
(ketoprofen), p < 0.05. In panels b and d, asterisks (*) indicate significant difference
from a “0” drug dose (i.e. vehicle) + lactic acid vehicle, dollar signs ($) indicate
significant difference from a “0” drug dose + lactic acid, and number signs (#) indicate
significant depression of ICSS by lactic acid as determined by two-way ANOVA followed
by Holm-Sidak post hoc test, p < 0.05. All bars show mean ± SEM in five rats
(CP55940) or four rats (ketoprofen).
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Figure 2.6

Figure 2.6. Chronic administration of THC produces tolerance to its rate-decreasing
effects on intracranial self-stimulation (ICSS) in the absence of a noxious stimulus.
Abscissa: THC challenge dose (mg/kg). Ordinate: percent baseline total number of
stimulations per component. Two-way ANOVA indicated a significant main effect of
chronic THC dose [F(3,12)=16.27; p<0.001], a significant main effect of THC challenge
dose [F(3,12)=55.33; p<0.001], and a significant interaction [F(9,36)=3.58; p=0.003].
Filled symbols indicate chronic THC + THC challenge dose combinations after which
reinforcement rates were significantly higher than rates after the same THC challenge
administered during chronic vehicle, as determined by Holm-Sidak post hoc test, p <
0.05. All bars show mean ± SEM in five rats.
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Figure 2.7

Figure 2.7. Chronic administration of THC produces partial tolerance to its
antinociceptive effects in the assay of acid-stimulated stretching but does not unmask
antinociceptive effects in the assay of acid-depressed intracranial self-stimulation
(ICSS). Abscissae (all panels): Day of THC (3.2 mg/kg/day) administration. Left
ordinate: number of stretches observed during 30 min observation periods. Right
ordinate: percent baseline total number of stimulations per component. Effects of a 2week washout period following chronic THC administration are also shown for
comparison but were not included in the statistical analysis. The left panel (a) shows the
effects of chronic administration of THC in the assay of acid-stimulated stretching. Oneway ANOVA indicated a significant main of THC treatment duration (panel a,
[F(4,20)=9.41; p<0.001]). Asterisks (*) indicate treatment with THC produced significant
antinociception compared to treatment with THC vehicle on days 1, 8, 15, and 22 of
chronic THC administration, and dollar signs ($) indicate significant tolerance to this
antinociceptive effect on day 15 compared to day 1 of chronic THC administration as
determined by Newman-Keul’s post hoc test, p < 0.05. The right panel (b) shows the
effects of chronic administration of THC in the assay of acid-depressed ICSS. One-way
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ANOVA indicated a significant main effect of treatment (panel b, [F(5,20)=10.08;
p<0.001]). Asterisks (*) indicate treatment with acid significantly depressed ICSS
compared to treatment with lactic acid vehicle as determined by Newman-Keul’s post
hoc test, p < 0.05. Chronic THC administration failed to alter THC effects on acidinduced depression of ICSS. All bars show mean ± SEM in six rats (stretching) or five
rats (ICSS).
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Figure 2.8
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Figure 2.8. THC and ketoprofen effects on feeding depressed by acid or prefeeding.
The upper left panel (a) shows the effects of lactic acid vehicle, lactic acid (0.56-1.8%),
or a 60 min prefeeding session on feeding. Abscissa: percent acid concentration.
Ordinates (all panels): percent body weight food consumed in grams during a 30 min
feeding session. One-way ANOVA indicated a significant main effect of treatment
[F(4,20)=16.30; p<0.001]. Asterisks (*) indicate lactic acid (1-1.8%) or a 60 min
prefeeding session significantly decreased feeding as determined by Dunnett’s post hoc
test, p < 0.05. All bars show mean ± SEM in six rats. The upper right panel (b) shows
effects of THC (0.32-3.2 mg/kg), ketoprofen (1 mg/kg), or vehicle administered 30 min
before acid vehicle treatment on control feeding. Abscissa: drug dose in milligrams per
kilogram. THC and ketoprofen did not significantly alter feeding in the absence of lactic
acid or a 60 min prefeeding session. All bars show mean ± SEM in seven rats. The
middle left panel (c) shows the effects of THC (0.32-1 mg/kg), ketoprofen (1 mg/kg), or
vehicle administered 30 min before 1.8% lactic acid. Abscissa: drug dose in milligrams
per kilogram. One-way ANOVA indicated a significant main effect of treatment
[F(4,24)=10.46; p<0.001]. The asterisk (*) indicates ketoprofen significantly blocked
acid-induced depression of feeding as determined by Dunnett’s post hoc test, p < 0.05.
All bars show mean ± SEM in seven rats. The middle right panel (d) shows the effects
of THC (0.1-1 mg/kg), ketoprofen (1 mg/kg), or vehicle administered immediately after a
60 min prefeeding session and 30 min before the test session. Abscissa: drug dose in
milligrams per kilogram. One-way ANOVA indicated a significant main effect of
treatment [F(4,28)=2.88; p=0.041]. The asterisk (*) indicates THC significantly blocked
prefeeding-induced depression of feeding as determined by Dunnett’s post hoc test, p <
0.05. All bars show mean ± SEM in eight rats. The bottom left panel (e) shows the
effects of CP55940 (0.0032-0.032 mg/kg or vehicle) administered 30 min before 1.8%
lactic acid. One-way ANOVA indicated a significant main effect of acid treatment
[F(4,28)=19.64; p<0.001]. Asterisks (*) indicate lactic acid (1.8%) significantly
decreased feeding as determined by Newman-Keuls post hoc test, p < 0.05. All means
± SEM represent eight rats. The bottom right panel (f) shows the effects of CP55940
(0.0032-0.032 mg/kg or vehicle) administered immediately after a 60 min prefeeding
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session and 30 min before the test session. One-way ANOVA indicated a significant
main effect of prefeeding treatment [F(4,28)=4.25; p=0.008]. Asterisks (*) indicate a 60
min prefeeding session significantly decreased feeding vs. CP55940 vehicle alone as
determined by Newman-Keuls post hoc test, p < 0.05. CP55940 did not alter feeding
under either condition tested. All means ± SEM represent eight rats.
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2.4. Discussion
The purpose of this study was to assess effects of the cannabinoid receptor
agonists THC and CP55940 in assays of pain-stimulated and pain-depressed behavior
in rats. There were four main findings. First, in agreement with the large literature on
antinociceptive effects of cannabinoid agonists in assays of pain-stimulated behavior
(Rice, 2006; Karst et al., 2010), THC and CP55940 dose-dependently decreased acidstimulated stretching. Second, THC and CP55940 also decreased control ICSS in the
absence of the acid noxious stimulus; however, depression of control ICSS was shorter
in duration (THC) or occurred at lower doses (CP55940) than depression of acidstimulated stretching. Furthermore, chronic administration of THC produced complete
tolerance to THC-induced depression of control ICSS and only produced partial
tolerance to THC-induced antinociception in the assay of acid-stimulated stretching.
These findings suggest that nonselective behavioral depression may have contributed
to, but could not account entirely for, cannabinoid antinociception in the assay of acidstimulated stretching. Third, despite evidence for antinociception in the assay of acidstimulated stretching, both acute and chronic THC and acute CP55940 failed to produce
antinociception in the assay of acid-depressed ICSS. Lastly, THC and CP55940 also
failed to produce antinociception in the assay of acid-depressed feeding. Collectively,
these findings demonstrate that although cannabinoid agonists are effective to produce
antinociception in assays of pain-stimulated behavior, they are ineffective in assays of
acute pain-depressed behavior. The effects of THC and CP55940 contrast with the
antinociceptive efficacy of clinically effective analgesics such as ketoprofen (Kwilasz
and Negus, 2012, present study) and morphine (Negus et al., 2006; Pereira Do Carmo
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et al., 2009) in these assays of pain-depressed behavior. Moreover, the lack of
cannabinoid efficacy in these assays of acute pain-depressed behavior in rats agrees
with the general lack of efficacy of cannabinoids in treating acute pain in humans (Raft
et al., 1977; Rice, 2006; Karst et al., 2010; Kraft, 2012). Taken together, these results
do not support the use of cannabinoid agonists to treat the behavioral depressant
effects of acute pain and further suggest that preclinical assays of pain-depressed
behavior may be useful during cannabinoid drug development for predicting clinical drug
effects on pain in humans.
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CHAPTER THREE
Effects of the FAAH inhibitors URB597 and PF3845
on acute pain-stimulated and pain-depressed behavior.
Submitted to the Journal of Pain in March 2013

3.1. Introduction
FAAH inhibitors increase physiological levels of the endocannabinoid AEA (which
targets CB1Rs and CB2Rs) as well as other fatty acid ethanolamines such as PEA and
OEA (which target PPAR-α). FAAH inhibitors such as URB597 and PF3845, like mixed
cannabinoid agonists, produce antinociception in many traditional preclinical assays of
pain but, unlike cannabinoid agonists, have been shown to produce fewer side effects
than traditional cannabinoid agonists such a sedation/motor suppression (Schlosburg et
al., 2009; Alvarez-Jaimes and Palmer, 2011). Recently, a clinical trial for the treatment
of osteoarthritis-related pain failed with the FAAH inhibitor PF7845, which is structurallyrelated to PF3845. This disparity between preclinical and clinical findings suggests that
traditional preclinical assays of pain used to study FAAH inhibitors in animals may not
be sufficient alone to predict clinical analgesic effects in humans.
The goal of the present study was to compare effects of the two wellcharacterized FAAH inhibitors URB597 and PF3845 in preclinical assays of acute painstimulated and pain-depressed behavior in rats. Assays of pain-stimulated and paindepressed behavior have been used previous to examine the effects of opioids,
nonsteroidal anti-inflammatory drugs, and other drug classes (Pereira Do Carmo et al.,
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2009; Negus et al., 2010b; Kwilasz and Negus, 2012; Negus et al., 2012; Rosenberg et
al., 2013). In particular, we have previously shown that the CBR agonists THC and
CP55940 failed to produce antinociception in assays of pain-depressed behavior
(Kwilasz and Negus, 2012, Chapter 2), a finding concordant with the poor clinical
efficacy of CBR agonists as analgesics in humans (Raft et al., 1977; Rice, 2006; Karst
et al., 2010; Kraft, 2012). Insofar as FAAH inhibitors display weaker efficacy than direct
CBR agonists to produce motor impairment, we predicted that URB597 and PF3845
might be more likely than CBR agonists to produce antinociception in assays of paindepressed behavior.

3.2. Methods
Subjects
One hundred and two male Sprague-Dawley rats (Harlan, Frederick, MD, USA)
weighing approximately 300 g at the time of delivery were used in these studies. All
housing, maintenance, and research conditions in this chapter are identical to those
described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter
Two of this dissertation.

Assay of acid-stimulated stretching
Behavioral procedure. Thirty-four rats that failed to meet the criteria for ICSS
within 4 weeks (see below) were used for studies of lactic acid-stimulated stretching as
described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter
Two of this dissertation.
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In four separate groups of rats, FAAH inhibitor dose-effect curves were
determined for URB597 (1-10 mg/kg or vehicle) or PF3845 (1-10 mg/kg or vehicle)
administered 60 min or 240 min prior to acid (i.e. 1 group/drug/time point). These
pretreatment times were selected based on previous studies that reported peak brain
levels of AEA, PEA, and OEA approximately 60 min post-treatment with URB597 and
approximately 240 min post-treatment with PF3845 (Fegley et al., 2005; Ahn et al.,
2009). To determine whether URB597-induced antinociception was mediated by CB1Rs
or CB2Rs, URB597 (10 mg/kg) was administered 240 min before acid in combination
with the CB1R-selective antagonist rimonabant (1 mg/kg) or the CB2R-selective
antagonist SR144528 (1 mg/kg) administered 30 min before acid. These antagonist
doses and pretreatment times were based on previous studies that have demonstrated
antagonism of cannabinoid agonist-induced antinociception with rimonabant (Kwilasz
and Negus, 2012) and SR144528 (Hohmann et al., 2004). Rimonabant and SR144528
were administered after URB597 because of their ability to act as competitive
antagonists at CB1Rs (Thomas et al., 1998; Jarbe et al., 2010) and CB2Rs (Griffin et
al., 1999), respectively. To determine whether URB597-induced antinociception was
mediated by PPAR-α, the PPAR-α antagonist MK886 (1-3.2 mg/kg) was administered
30 min before URB597 (10 mg/kg), which was administered 240 min before acid. The
doses and treatment time for MK886 were based on previous studies that demonstrated
antagonism of URB597 and PPAR-α agonist effects with MK886 (Mazzola et al., 2009;
Mascia et al., 2011). MK886 was administered prior to URB597 to ensure blockade of
the transcription-enhancing effects of PEA, OEA, which have been implicated in their
therapeutic effects (Schoonjans et al., 1996; Gervois and Mansouri, 2012). PF3845-
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induced pronociception was also assessed for mediation by CB1/2Rs and PPAR-α
using identical procedures to those used for URB597. Doses/treatments for all phases
were delivered in a randomized dose order across rats and separated by at least one
week.
Data Analysis. All methods of data analysis in this chapter are identical to those
described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter
Two of this dissertation.

Assay of intracranial self-stimulation (ICSS)
Surgery. All surgical procedures in this chapter are identical to those described
previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter Two of
this dissertation.
Apparatus. All apparatus and materials used in this chapter are identical to
those described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in
Chapter Two of this dissertation.
Behavioral procedure. After initial shaping of lever press responding, rats were
trained under a continuous reinforcement schedule of brain stimulation using
procedures identical to those described previously (Kwilasz and Negus, 2012;
Rosenberg et al., 2013) and in Chapter Two of this dissertation.
Studies of FAAH inhibitor effects on ICSS were conducted in three phases, and
the experimental design of each phase is shown in Figure 3.1. In the first phase,
subjects were treated with URB597 (1-10 mg/kg or vehicle) or PF3845 (1-10 mg/kg or
vehicle) at time “0” and with the intraperitoneal acid noxious stimulus (1.8% lactic acid in
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a volume of 1 ml/kg) administered 60 min later. ICSS was evaluated for 20 min before
and 20 min after acid injection to assess FAAH inhibitor effects in the absence and
presence of the noxious stimulus. Specifically, ICSS was evaluated from 40-60 min to
assess effects of the FAAH inhibitor in the absence of the noxious stimulus and again
from 60-80 min to assess effects of the FAAH inhibitor on acid-induced depression of
ICSS. The second phase was identical except that the acid noxious stimulus was
administered 260 min after the FAAH inhibitor, and ICSS was assessed from 240-260
min (FAAH inhibitor effects on ICSS in the absence of the noxious stimulus) and from
260-280 min (FAAH inhibitor effects on acid-induced depression of ICSS). In the third
phase, to determine whether URB597-induced antinociception in the assay of aciddepressed ICSS was mediated by CB1Rs or CB2Rs, URB597 (10 mg/kg) was
administered at time “0”, either rimonabant (1 mg/kg) or SR144528 (1 mg/kg) was
administered after 210 min, and the acid noxious stimulus was administered after 260
min. Lastly, in the fourth phase, to determine whether URB597-induced antinociception
in the assay of acid-depressed ICSS was mediated by PPAR-α, MK886 (1-3.2 mg/kg)
was administered 30 min prior to URB597 (10 mg/kg), which was administered at time
“0,” and the acid noxious stimulus was administered after 260 min. ICSS was evaluated
for 20 min before and 20 min after acid injection in phases three and four as in the other
phases. FAAH inhibitor doses and cannabinoid/PPAR-α antagonist + URB597
combinations were administered in randomized order and were separated by at least
one week. Training and test sessions were conducted Monday-Friday, with test
sessions conducted on Wednesdays, Thursdays, or Fridays.
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Data Analysis. All methods of data analysis in this chapter are identical to those
described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter
Two of this dissertation.

Measurement of brain and plasma fatty acid ethanolamines
Experimental procedure. Forty-three rats were used for the measurement of
brain and plasma fatty acid ethanolamines following FAAH inhibitor administration. The
fatty acid ethanolamines evaluated were anandamide (AEA), palmitoylethanolamide
(PEA), and oleoylethanolamide (OEA). Rats were dosed in their home cages with
URB597 (10 mg/kg, vehicle) or PF3845 (10 mg/kg, vehicle) and sacrificed via
decapitation with guillotine at 60 or 240 min after drug administration. Naive rats that did
not receive any injection prior to sacrifice were also included as controls. Immediately
after decapitation, brains were harvested, quickly frozen in isopentane on dry ice, and
stored at -80°C until assay. For plasma samples, trunk blood was collected immediately
after decapitation and centrifuged at 1250 x g to separate plasma from blood cells.
Plasma samples were then stored at -80°C until assay.
Procedure for tissue extraction. On the day of assay, the pre-weighed rat
brains were homogenized with 5 ml chloroform:methanol (2:1 v/v containing 0.0348 g
PMSF/ml). One quarter of the homogenate (1.25 ml) was taken and diluted to 1.4 ml
with the chloroform:methanol used for homogenization. Internal standards (50 µl of each
of 2 pmol AEA-d8, 1 nmol 2-AG-d8, 3.3 nmol PEA-d4 and 3 nmol OEA-d4) were added
to each sample. Homogenates were vortexed and mixed with 0.3 ml of 0.73% w/v NaCl,
vortexed again, and then centrifuged for 10 min at 3200 x g and 4°C. The aqueous
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phase plus debris were collected and extracted again twice with 0.8 ml chloroform. The
organic phases from the three extractions were pooled, and organic solvents were
evaporated under nitrogen gas. Dried samples were reconstituted with 0.1 ml
chloroform and mixed with 1 ml cold acetone. The mixtures were then centrifuged for 5
min at 1800 x g and 4°C to precipitate proteins. The upper layer of each sample was
collected and evaporated under nitrogen gas. Dried samples were reconstituted with 0.1
ml methanol and placed in auto-sample vials for analysis.
Rat plasma (200 µl) was mixed with 50 µl of each of the internal standards
mentioned above and then mixed with 2.8 ml chloroform:methanol (2:1 containing
0.0348 g PMSF/ml). Samples were vortexed and 0.6 ml of 0.73% w/v NaCl was added
to each sample, vortexed, and then centrifuged for 10 min at 3200 x g and 4°C. The
aqueous phase plus debris were collected and extracted again twice with 1.6 ml
chloroform. The organic phases from the three extractions were pooled and the organic
solvents were evaporated under nitrogen gas. The dried samples were reconstituted
with 0.1 ml chloroform and mixed with 1 ml cold acetone. The upper layer of each
sample was then collected and processed as described above.
High performance liquid chromatography tandem mass spectrometry
(HPLC/MS/MS) quantification. An HPLC/MS/MS system was used to identify and
quantify AEA, 2-AG, PEA, and OEA in brain and plasma samples. The system used
was a 3200 Q trap with a turbo V source for TurbolonSpray (Applied Biosystems,
Carlsbad, CA, USA) attached to a SCL HPLC system (Shimadzu, Kyoto, Japan)
controlled by Analyst 1.4.2 software (AB Sciex, Framingham, MA, USA). The
chromatographic separation was performed using a Discovery HS C18, 4.6 x 15 cm, 3
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micron (Supelco, Bellefonte, PA, USA). The mobile phase consisted of (10:90)
water:methanol with 0.1% ammonium acetate and 0.1% formic acid and was delivered
at a flow rate of 0.3 ml/min. The source temperature was set at 600°C and had a curtain
gas at a flow rate of 30 ml/min. The ionspray voltage was 5000 V with ion source gases
1 and 2 flow rates of 60 and 50 ml/min, respectively. The mass spectrometer was run in
positive ionization mode, and the acquisition mode used was multiple reaction
monitoring. The following transitions were monitored: (348>62) and (348>91) for AEA;
(356>62) for AEA-d8; (379>287) and (279>269) for 2-AG; (387>96) for 2-AG-d8;
(300>62) and (300>283) for PEA; (304>62) for PEA-d4; (326>62) and (326>309) for
OEA; and (330>66) for OEA-d4. Calibration curves were constructed with each
analytical batch for each analyte. Curves were constructed using linear regression
based on the peak area ratios of each analyte and its deuterated internal standard. The
extracted calibration curves ranged from 0.039 pmol to 40 pmol for AEA, from 0.0625
nmol to 64 nmol for 2-AG, and from 0.156 nmol to 0.5 nmol for PEA and OEA. The total
run time for the analytical method was 8 minutes.
Data Analysis. Prior to data analysis, AEA brain level data were transformed to
pmol/g of brain tissue, 2-AG, PEA, and OEA brain level data were transformed to
nmol/g of brain tissue, and AEA, PEA, and OEA plasma level data were transformed to
pmol/ml of plasma. 2-AG plasma levels were below the threshold of detection.
Statistical analysis of brain and plasma levels of AEA, PEA, and OEA did not reveal
significant differences between naïve and vehicle-treated animals; thus drug-treatment
levels were normalized to mean vehicle-treatment levels for each condition using the
equation: (Drug-Treatment Level ÷ Mean Vehicle-Treatment Level) x 100. Drug effects
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on brain and plasma fatty acid amides were evaluated by two-way ANOVA, with
treatment and treatment time as the two factors. A significant ANOVA was followed by
Holm-Sidak post hoc test, and the criterion for significance was set at p < 0.05.

Drugs
Lactic acid was purchased from Sigma Chemical Co. (St. Louis, MO, USA). AEA,
AEA-d8, 2-AG, 2-AG-d8, PEA, PEA-d4, OEA, OEA-d4, and MK886 were purchased
from Cayman Chemical (Ann Arbor, MI, USA). URB597, rimonabant, and SR144528
were provided by the National Institute on Drug Abuse Drug Supply Program (Bethesda,
MD, USA). PF3845 was provided by Dr. Ben Cravatt at The Scripps Research Institute
(San Diego, CA, USA) and by Anu Mahadevan at Organix Laboratories (Woburn, MA,
USA). Lactic acid was prepared in sterile water. MK886 was prepared in a vehicle
consisting of 20% DMSO and 80% sterile water. URB597 was prepared in a vehicle
consisting of 1% carboxymethylcellulose (Sigma), 1% Tween 80 (Sigma), 2% dimethyl
sulfoxide (Sigma), and 96% sterile saline. PF3845 was prepared in a vehicle consisting
of 10% ethanol, 10% emulphor EL-620 (Rhone-Poulenc; Princeton, NJ, USA), and 80%
sterile saline. Rimonabant and SR144528 were prepared in a vehicle consisting of 5%
ethanol, 5% cremophor (Sigma), and 90% sterile saline. All solutions were injected
intraperitoneally in a volume of 1 ml/kg except for URB597, which was injected
intraperitoneally in a volume of 2 ml/kg.
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3.3. Results
Effects of FAAH inhibitors on acid-stimulated stretching. Figure 3.2 shows
that IP administration of lactic acid (1.8% in a volume of 1 ml/kg) stimulated
approximately 15 stretches after administration of vehicle (gray bars in all panels).
URB597 (1-10 mg/kg) dose-dependently and significantly decreased stretching after
both 60 and 240 min (panels 3.2a and 3.2c, respectively). Conversely, PF3845 (1-10
mg/kg) had no effect on stretching after 60 min (panel 3.2b), and it dose-dependently
increased stretching after 240 min (panel 3.2d; an effect that was replicated in a
separate group of rats and found to be insensitive to rimonabant, data not shown).
Figure 3.3 shows that the antinociceptive effect of URB597 in the assay of acidstimulated stretching was antagonized by administration of the CB1R antagonist
rimonabant (1 mg/kg, panel 3.3a), but not by the CB2R antagonist SR144528 (1 mg/kg,
panel 3.3b) or the PPAR-α antagonist MK886 (1-3.2 mg/kg, panel 3.3c). Rimonabant,
SR144528, and MK886 did not alter acid-stimulated stretching when administered
alone. Figure 3.4a shows that the pronociceptive effect of PF3845 in the assay of acidstimulated stretching was not antagonized by administration of the CB1R antagonist
rimonabant (1 mg/kg) or CB2R antagonist SR144528 (1 mg/kg). Figure 3.4b also shows
that the pronociceptive effect of PF3845 in the assay of acid-stimulated stretching was
not able to be repeated enough times to properly determine the effect of MK886 on
PF3845-induced pronociception. Nonetheless, stretching is highest after MK886 +
PF3845 versus PF3485 alone and vehicle, suggesting PPAR-α is not likely to play a
role in PF3845-induced pronociception.
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Effects of FAAH inhibitors on ICSS in the absence of a noxious stimulus.
Over the course of the entire ICSS study, the average baseline number of stimulations
per component was 188.31 ± 45.91, and data in Figures 3.5, 3.7, and 3.9 show drug
effects expressed as a percent of the baseline number of stimulations per component in
each group of rats. Figure 3.5 shows that both URB597 (1-10 mg/kg) and PF3845 (1-10
mg/kg) produced dose-dependent decreases in ICSS from 40-60 min after treatment,
but not from 240-260 min after treatment, in the absence of the noxious stimulus.
During each test session, a “baseline” frequency-rate curve was determined
before testing to permit determination of the Maximum Control Rate (MCR) for that
session. Over the course the entire study in all groups of rats, the average MCR was
51.56 ± 4.95 stimulations/trial. Reinforcement rates during each frequency trial of a
session were then expressed as a percentage of that session’s MCR, and the average
baseline frequency-rate curves for studies with URB597 and PF3845 are shown in
Figure 3.6 as gray lines. Maximum reinforcement rates were usually observed at the
highest stimulation frequencies and decreased with lower stimulation frequencies. In
general, when administered 40 min prior to an ICSS session, both URB597 and PF3845
produced rightward and downward shifts in the ICSS frequency-rate curves (Figs. 3.6a
and b). Forty min after administration of URB597, a low dose of 1 mg/kg URB597
increased ICSS at a single frequency of 158 Hz, whereas higher doses of 3.2 and 10
mg/kg URB597 significantly decreased ICSS at frequencies of 126, 141, and 158 Hz
(Fig. 3.6a). Forty minutes after administration of PF3845, low doses of 1 and 3.2 mg/kg
PF3845 produced no effect on ICSS, whereas a higher dose of 10 mg/kg PF3845
significantly decreased ICSS at a single frequency of 141 Hz (Fig. 3.6b). Both URB597
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and PF3845 produced less dramatic rate-decreasing effects when administered 240
min prior to an ICSS session (Figs. 3.6c and d). Following 240 min administration with
URB597, a low dose of 1 mg/kg URB597 significantly decreased ICSS at a frequency of
141 Hz, a higher dose of 3.2 mg/kg URB597 significantly decreased and increased
ICSS at frequencies of 158 Hz and 89 Hz, respectively, and the highest dose of 10
mg/kg URB597 significantly increased ICSS at a frequency of 89 Hz (Fig. 3.6c).
Following 240 min administration with PF3845, low doses of 1 and 3.2 mg/kg PF3845
produced no effect on ICSS, whereas a higher dose of 10 mg/kg PF3845 significantly
decreased ICSS at frequencies of 112 and 126 Hz (Fig. 3.6d).
Effects of FAAH inhibitors on acid-induced depression of ICSS. Figure 3.7
shows that the lactic acid noxious stimulus significantly decreased ICSS when it was
administered 60 min or 260 min after vehicle. This acid-induced depression of ICSS
served as a manifestation of pain-related behavioral depression, and drugs were
evaluated for their ability to block acid-induced depression of ICSS. Figure 3.7 also
shows that URB597 but not PF3845 produced dose- and time-dependent
antinociception in the assay of acid-depressed ICSS. Specifically, URB597 (1-10 mg/kg)
did not significantly alter acid-induced depression of ICSS after 60 min (panel 3.7a), but
it partially, dose-dependently and significantly attenuated acid-induced depression of
ICSS after 260 min (panel 3.7c). Conversely, PF3845 (1-10 mg/kg) did not significantly
alter acid-induced depression of ICSS after either 60 (panel 3.7b) or 260 min (panel
3.7d).
Both URB597 and PF3845 displayed small but significant antinociceptive effects
in the assay of acid-induced depression of ICSS based on the frequency-rate curve

70
analysis (Fig. 3.8). URB597 (10 mg/kg) administered 260 min before acid treatment
significantly attenuated acid-induced depression of ICSS at a single frequency of 126
Hz, however this point was also significantly different than URB597 vehicle + acid
vehicle treatment (Fig. 3.8c). PF3845 (3.2-10 mg/kg) administered 60 min before acid
treatment also significantly attenuated acid-induced depression of ICSS (Fig. 3.8b). A
dose of 3.2 mg/kg PF3845 significantly attenuated acid-induced depression of ICSS at
frequencies of 141 and 158 Hz, and a dose of 10 mg/kg PF3845 significantly attenuated
acid-induced depression of ICSS at a single frequency of 158 Hz. URB597 (1-10 mg/kg)
administered 60 min before acid treatment and PF3845 (1-10 mg/kg) administered 260
min before acid treatment produced no effects on acid-induced depression of ICSS.
Figure 3.9 (panels a and b) show that the CB1R antagonist rimonabant and the
CB2R antagonist SR144528 failed to reverse URB597-induced antinociception in the
assay of acid-depressed ICSS. Administration of 1 mg/kg rimonabant (Fig. 3.9a) or 1
mg/kg SR144528 (Fig. 3.9b) 50 min before the ICSS session had no effect on the
antinociceptive effects of 10 mg/kg URB597 administered 260 min before the ICSS
session. Furthermore, these doses of rimonabant (Fig. 3.9a) and SR144528 (Fig. 3.9b)
produced no effects on acid-induced depression of ICSS alone. Experiments with the
PPAR-α antagonist MK886 were less straightforward (Figure 3.9c). In this group of rats,
URB597 (10 mg/kg) produced statistically ambiguous evidence for antinociception, such
that ICSS after URB597 + acid was not statistically different from ICSS after either acid
vehicle alone or acid alone, and MK886 did not significantly alter these weak effects of
URB597.
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Effects of FAAH inhibitors on plasma and brain fatty acid ethanolamines.
Figure 3.10 shows that both URB597 (10 mg/kg) and PF3845 (10 mg/kg) produced
time-dependent increases in plasma and brain fatty acid ethanolamines. URB597
increased plasma PEA and OEA after 60 and 240 min; however it did not significantly
increase plasma AEA at either of these times. In brain, URB597 increased AEA and
OEA after 60 min and AEA, OEA and PEA after 240 min. PF3845 increased plasma
AEA and OEA after 60 min and AEA, OEA, and PEA after 240 min. In brain, PF3845
increased AEA, OEA, and PEA after 240 min but not 60 min. No significant differences
were found in brain levels of 2-AG after administration of either FAAH inhibitor at any
time point (data not shown). Levels of endocannabinoids/fatty acid ethanolamines in
naïve animals were as follows: in plasma in pmol/ml, AEA (0.90 ± 0.18), PEA (16.81 ±
3.11), and OEA (9.16 ±1.47), and in brain in pmol/g, AEA (5.26 ± 1.41), and in nmol/g,
PEA (0.21 ± 0.06), OEA (0.08 ± 0.01), and 2-arachidonoylglycerol (9.49 ± 1.04). 2-AG
levels in plasma were below the limits of detection for all treatments.
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Figure 3.1

Figure 3.1. Diagram of experimental design used for drug treatments and behavioral
testing in the assay of acid-depressed intracranial self-stimulation (ICSS).
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Figure 3.2

Figure 3.2. Effects of FAAH inhibitors on acid-stimulated stretching. Abscissae: dose
FAAH inhibitor in milligrams per kilogram. Ordinates: number of stretches observed
during a 30 min observation period. The left panels (a and c) show the effects of
URB597 (1-10 mg/kg or vehicle) administered 60 min (panel a) or 240 min (panel c)
before acid treatment. One-way repeated measures ANOVA indicated significant main
effects of URB597 after 60 min (panel a) [F(3,15)=9.59; p<0.001] and 240 min (panel c)
[F(3,12)=14.63; p<0.001]. All bars show mean ± SEM in six (60 min) or five (240 min)
rats. The right panels (b and d) show the effects of PF3845 (1-10 mg/kg or vehicle)
administered 60 min (panel b) or 240 min (panel d) before acid treatment. One-way
repeated measures ANOVA indicated a significant main effect of PF3845 treatment 240
min post-treatment (panel d) [F(4,20)=11.71; p<0.001]. All bars show mean ± SEM in
six rats. Asterisks (*) indicate significantly different from vehicle + acid in all panels as
determined by Dunnett’s post hoc test, p < 0.05.
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Figure 3.3

Figure 3.3. URB597-induced antinociception in the assay of acid-stimulated stretching
is antagonized by rimonabant but not by SR144528 or MK886. Abscissae: Treatment
conditions. Ordinates: number of stretches observed during a 30 min observation
period. The left panel (a) shows the effect of URB597 (10 mg/kg or vehicle)
administered 240 min before acid treatment in combination with rimonabant (1 mg/kg or
vehicle) administered 30 min before acid treatment. One-way repeated measures
ANOVA indicated a significant main effect of treatment in panel a [F(3,9)=9.47;
p=0.004]. The center panel (b) shows the effect of URB597 (10 mg/kg or vehicle)
administered 240 min before acid treatment in combination with SR144528 (1 mg/kg or
vehicle) administered 30 min before acid treatment. One-way repeated measures
ANOVA indicated a significant main effect of treatment in panel b [F(3,9)=17.03;
p<0.001]. The right panel (c) shows the effect of MK886 (1-3.2 mg/kg or vehicle)
administered 30 min before URB597 (10 mg/kg or vehicle), which was administered 240
min before acid treatment. One-way repeated measures ANOVA indicated a significant
main effect of treatment in panel c [F(5,15)=7.27; p=0.001]. Asterisks (*) in all panels
indicate significantly different from vehicle + acid, and the dollar sign ($) in panel a
indicates significantly different from URB597 (10 mg/kg) + acid as determined by
Newman-Keuls post hoc test, p < 0.05. All bars show mean ± SEM in four rats.
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Figure 3.4
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Figure 3.4. PF3845-induced pronociception in the assay of acid depressed ICSS is not
antagonized by rimonabant, SR144528, or MK886. Abscissae: Treatment conditions.
Ordinates: percent baseline total number of stimulations per component. The left panel
(a) shows the effects of PF3845 (10 mg/kg or vehicle) administered 240 min before acid
treatment in combination with rimonabant (1 mg/kg) or SR144528 (1 mg/kg)
administered 30 min before acid treatment. One-way repeated measures ANOVA
indicated a significant main effect of PF3845 treatment in panel a [F(3,21)=5.56;
p=0.006]. Asterisks (*) in panel a indicate significantly different from vehicle + acid
treatment as indicated by Newman-Keuls post hoc test, p < 0.05. All bars show mean ±
SEM in eight rats. The right panel (b) shows the effects of PF3845 (10 mg/kg or vehicle)
administered 240 min before acid treatment in combination with MK886 (1 mg/kg)
administered 30 min before PF3845 treatment. One-way repeated measures ANOVA
did not indicate an effect of treatment. All bars show mean ± SEM in seven rats.
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Figure 3.5

Figure 3.5. Effects of URB597 and PF3845 on control ICSS in the absence of a
noxious stimulus. Abscissae: dose FAAH inhibitor in milligrams per kilogram. Ordinates:
percent baseline total number of stimulations per component. The left panels (a and c)
show the effects of URB597 (1-10 mg/kg or vehicle) administered 40 min (panel a) or
240 min (panel c) before ICSS. One-way repeated measures ANOVA indicated a
significant main effect of URB597 treatment 40 min post-treatment (panel a)
[F(3,12)=13.47; p<0.001]. The right panels (b and d) show the effects of PF3845 (1-10
mg/kg or vehicle) administered 40 min (b) or 240 min (d) before ICSS. One-way
repeated measures ANOVA indicated a significant main effect of PF3845 treatment 40
min post-treatment (panel b) [F(3,12)=5.51; p=0.013]. Asterisks (*) in all panels indicate
significantly different from vehicle treatment as indicated by Dunnett’s post hoc test, p <
0.05. All bars show mean ± SEM in five rats.
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Figure 3.6

Figure 3.6. Full ICSS frequency-rate curves for Figure 3.5. Abscissae: frequency of
electrical brain stimulation in hertz (log scale). Ordinates: percent maximum control
response rate (%MCR). The left panels (a and c) show ICSS frequency-rate curves
determined 40 min (panel a) or 240 min (panel c) after treatment with URB597 (1-10
mg/kg or vehicle). The average baseline ICSS frequency-rate curve for each study is
shown by the gray line for comparison, but these data were not included in statistical
analysis. Two-way repeated measures ANOVA indicated a significant main effect of
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URB597 treatment in panel a [F(3,12)=15.89, p<0.001], a significant main effect of
frequency in panels a [F(9,36)=41.79; p<0.001]) and c [F(9,36)=14.61; p<0.001]), and a
significant treatment × frequency interaction panels a [F(27,108)=7.38; p<0.001]) and c
[F(27,108)=1.61; p=0.045]). The right panels (b and d) show ICSS frequency-rate
curves determined 40 min (panel b) or 240 min (panel d) after treatment with PF3845
(1-10 mg/kg or vehicle). Two-way repeated measures ANOVA indicated a significant
main effect of PF3845 treatment in panel b [F(3,12)=5.00; p=0.018], a significant main
effect of frequency in panels b [F(9,36)=47.94; p<0.001]) and d [F(9,36)=44.66;
p<0.001]), and a significant treatment × frequency interaction in panel d
[F(27,108)=2.81; p<0.001]). Filled symbols indicate frequencies at which reinforcement
rates after URB597 or PF3845 treatment were significantly different than rates after
vehicle treatment as determined by Holm-Sidak post hoc test, p < 0.05. All data show
mean ± SEM in five rats.
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Figure 3.7

Figure 3.7. Effects of URB597 and PF3845 on acid-induced depression of ICSS.
Abscissae: dose FAAH inhibitor in milligrams per kilogram. Ordinates: percent baseline
total number of stimulations per component. The left panels (a and c) show the effects
of URB597 (1-10 mg/kg or vehicle) administered 60 min (panel a) or 260 min (panel c)
before acid treatment. One-way repeated measures ANOVA indicated a significant main
effect of treatment in panels a [F(4,16)=4.59; p=0.012] and c [F(4,16)=9.83; p<0.001].
The right panels (b and d) show the effects of PF3845 (1-10 mg/kg or vehicle)
administered 60 min (panel b) or 260 min (panel d) before acid treatment. One-way
repeated measures ANOVA indicated a significant main effect of treatment in panels b
[F(4,16)=17.73; p<0.001] and d [F(4,16)=10.96; p<0.001]. Asterisks (*) in all panels
indicate significantly different from vehicle + acid vehicle treatment, and dollar signs ($)
in panel c indicate significantly different from vehicle + acid treatment as indicated by
Newman-Keuls post hoc test, p < 0.05. All bars show mean ± SEM in five rats.

80
Figure 3.8

Figure 3.8. Full ICSS frequency-rate curves for Figure 3.7. Abscissae: frequency of
electrical brain stimulation in hertz (log scale). Ordinates: percent maximum control
response rate (%MCR). The left panels (a and c) show ICSS frequency-rate curves
determined in the presence of the acid noxious stimulus 60 min (panel a) or 260 min
(panel c) after treatment with URB597 (1-10 mg/kg or vehicle). Two-way repeated
measures ANOVA indicated a significant main effect of treatment in panels a
[F(4,16)=6.68; p=0.002] and c [F(4,16)=5.42 p=0.006]), a significant main effect of
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frequency in panels a [F(9,36)=24.42; p<0.001]) and c [F(9,36)=16.13; p<0.001]), and a
significant treatment × frequency interaction in panels a [F(36,144)=3.41; p<0.001]) and
c [F(36,144)=1.76; p=0.010]). The right panels (b and d) show ICSS frequency-rate
curves determined in the presence of the acid noxious stimulus 60 min (panel b) or 260
min (panel d) after treatment with PF3845 (1-10 mg/kg or vehicle). Two-way repeated
measures ANOVA indicated a significant main effect of PF3845 treatment in panels b
[F(4,16)=22.00; p<0.001] and d [F(4,16)=8.61; p<0.001]), a significant main effect of
frequency in panels b [F(9,36)=24.55; p<0.001]) and d [F(9,36)=21.97; p<0.001]), and a
significant treatment × frequency interaction in panels b [F(36,144)=4.05; p<0.001]) and
d [F(36,144)=4.46; p<0.001]). Black filled symbols indicate frequencies at which
reinforcement rates after vehicle + acid or drug + acid treatment were significantly lower
than rates after vehicle + acid vehicle treatment, gray filled symbols indicate frequencies
at which reinforcement rates after PF3845 + acid treatment were significantly higher
than rates after vehicle + acid treatment, and half-filled gray and black symbols indicate
frequencies at which reinforcement rates after URB597 + acid treatment were both
significantly lower than rates after vehicle + acid vehicle treatment and significantly
higher than rates after vehicle + acid treatment as determined by Holm-Sidak post hoc
test, p < 0.05. All data show mean ± SEM in five rats.
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Figure 3.9

Figure 3.9. URB597-induced antinociception in the assay of acid depressed ICSS is
not antagonized by rimonabant, SR144528, or MK886. Abscissae: Treatment
conditions. Ordinates: percent baseline total number of stimulations per component.
The left panel (a) shows the effects of URB597 (10 mg/kg or vehicle) administered 260
min before acid treatment in combination with rimonabant (1 mg/kg or vehicle)
administered 50 min before acid treatment. One-way repeated measures ANOVA
indicated a significant main effect of treatment in panel a [F(4,16)=13.68; p<0.001]. The
center panel (b) shows the effects of URB597 (10 mg/kg or vehicle) administered 260
min before acid treatment in combination with SR144528 (1 mg/kg or vehicle)
administered 50 min before acid treatment. One-way repeated measures ANOVA
indicated a significant main effect of treatment in panel b [F(4,16)=14.53; p<0.001]. The
right panel (c) shows the effects of MK886 (1-3.2 mg/kg or vehicle) administered 30 min
before URB597 (10 mg/kg or vehicle), which was administered 260 min acid treatment.
One-way repeated measures ANOVA indicated a significant main effect of treatment in
panel c [F(6,24)=5.46; p<0.001]. Asterisks (*) in all panels indicate significantly different
from vehicle + acid vehicle treatment, and dollar signs ($) in all panels indicate
significantly different from vehicle + acid treatment as indicated by Newman-Keuls post
hoc test, p < 0.05. All bars show mean ± SEM in five rats.
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Figure 3.10

Figure 3.10. Both URB597 and PF3845 produced time-dependent increases in plasma
and brain fatty acid ethanolamines. Abscissae: time post-drug administration in minutes.
Ordinates: percent of vehicle-treatment. All panels show the effects of URB597 (10
mg/kg or vehicle) and PF3845 (10 mg/kg or vehicle) on plasma (upper panels) and
brain (lower panels) levels of anandamide (AEA) (panels a and d),
palmitoylethanolamide (PEA) (panels b and e), and oleoylethanolamide (OEA) (panels c
and f). In plasma, two-way ANOVA indicated a significant main effect of treatment
(panel a [F(2,17)=37.17; p<0.001], panel b [F(2,17)=26.15; p<0.001], and panel c
[F(2,17)=71.77; p<0.0001]), a significant main effect of time (panel b [F(1,17)=8.06;
p=0.011] and panel c [F(1,17)=5.93; p=0.026]), and a significant treatment × time
interaction (panel c [F(2,17)=5.15; p<0.018]). In brain samples, two-way ANOVA
indicated a significant main effect of treatment (panel d [F(2,17)=22.92; p<0.001], panel
e [F(2,17)=69.14; p<0.001], and panel f [F(2,17)=59.62; p<0.001]), a significant main
effect of time (panel d [F(1,17)=10.11; p=0.006], panel e [F(1,17)=110.2; p<0.001], and
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panel f [F(1,17)=43.01; p<0.001]), and a significant treatment × time interaction (panel d
[F(2,17)=6.01; p=0.011], panel e [F(2,17)=61.68; p<0.001], and panel f [F(2,17)=12.36;
p<0.001]). Filled symbols indicate significantly different from vehicle treatment (i.e.
100%), asterisks (*) indicate a significant difference between URB597 and PF3845
treatment, number signs (#) indicate a significant difference in URB597 treatment 60
min versus 240 min post-treatment, and dollar signs ($) indicate a significant difference
in PF3845 treatment 60 min versus 240 min post-treatment as indicated by Holm-Sidak
post hoc test, p < 0.05. All points show mean ± SEM in four rats except for URB597 60
min post-treatment which shows mean ± SEM in three rats.
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3.4. Discussion
This study assessed effects of the FAAH inhibitors URB597 and PF3845 in
assays of pain-stimulated and pain-depressed behavior in rats. There were four main
findings. First, URB597 produced partial but dose-dependent antinociception in both
assays, and these results provide some support for further consideration of URB597 as
a candidate analgesic drug. Second, PF3845 failed to produce antinociception in either
assay, and the poor preclinical efficacy of PF3845 agrees with the poor clinical efficacy
of the structurally-related FAAH inhibitor PF7845 to treat osteoarthritis-related pain
(Huggins et al., 2012). Together, these findings highlight the potential for differential
effects by drugs with nominally similar mechanisms of action. Third, URB597-induced
antinociception in the assay of acid-stimulated stretching was mediated by CB1Rs, but
not CB2Rs or PPAR-α, whereas in the assay of acid-depressed ICSS, URB597-induced
antinociception was not mediated by CBRs or PPAR-α. Lastly, both URB597 and
PF3845 similarly increased biomarkers AEA, PEA, and OEA that have previously been
associated with antinociceptive effects of FAAH inhibitors (Ahn et al., 2009; Ahn et al.,
2011). These results challenge prevailing notions regarding the importance of FAAH
inhibition, AEA/fatty acid ethanolamine generation, and cannabinoid receptor/PPAR-α
activation in mediating the antinociceptive effects of FAAH inhibitors and suggest
differences in the potential of FAAH inhibitors as candidate analgesics for treatment of
acute pain.
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CHAPTER FOUR
Effects of the CB2R agonist GW405833
on acute pain-stimulated and pain-depressed behavior
Manuscript in preparation for submission for publication

4.1. Introduction
CBR agonists are classified by their ability to bind to and activate CB1Rs and/or
CB2Rs (Howlett, 1995; Pertwee, 2010). CB1Rs are located primarily on nerve cells
(Devane et al., 1988; Matsuda et al., 1990; Herkenham et al., 1991), whereas CB2Rs
have been found primarily on immune-related cells, such as macrophages and microglia
(Munro et al., 1993; Van Sickle et al., 2005; Wilkerson and Milligan, 2011). Both specific
CB1R agonists and CB2R agonists have been shown to produce antinociception in
many traditional preclinical assays of pain, however CB1R agonists have also been
associated with cannabimimetic-related side effects such as behavioral
depression/sedation, which has dampened overall clinical enthusiasm for these
compounds (Rice, 2006; Karst et al., 2010). In contrast, CB2R agonists do not produce
cannabimimetic-related side effects until they reach doses that produce nonspecific
CB1R-mediated effects (Anikwue et al., 2002; Valenzano et al., 2005; Whiteside et al.,
2005; Karst and Wippermann, 2009). Several CB2R agonists are in various stages of
clinical development (see Wilkerson and Milligan, 2011 for review); however, recently a
clinical trial for the treatment of dental-related pain failed with the CB2R agonist
GW842166 (Ostenfeld et al., 2011). This disparity between preclinical and clinical
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findings suggests that traditional preclinical assays of pain used to study CB2R agonists
in animals may not be sufficient alone to predict clinical analgesic effects in humans.
The goal of the present study was to assess the effects of the CB2R agonist
GW405833 in preclinical assays of acute pain-stimulated and pain-depressed behavior
in rats. Assays of pain-stimulated and pain-depressed behavior have been used
previous to examine the effects of opioids, nonsteroidal anti-inflammatory drugs, and
other drug classes (Pereira Do Carmo et al., 2009; Negus et al., 2010b; Kwilasz and
Negus, 2012; Negus et al., 2012; Rosenberg et al., 2013). We have previously shown
that the CBR agonists THC and CP55940 failed to produce antinociception in assays of
pain-depressed behavior (Kwilasz and Negus, 2012), a finding concordant with the poor
clinical efficacy of CBR agonists as analgesics in humans (Raft et al., 1977; Rice, 2006;
Karst et al., 2010; Kraft, 2012). We have also shown in Chapter 3 of this dissertation
that the FAAH inhibitor URB597 produces non-CBR-mediated antinociception in the
assay of pain-depressed behavior. Given that CB2R agonists display weaker efficacy
than CB1R agonists to produce motor impairment similar to FAAH inhibitors, we
predicted that GW405833 might be more likely than CB1R agonists to produce
antinociception in assays of pain-depressed behavior.

4.2. Methods
Subjects
Fifteen male Sprague-Dawley rats (Harlan, Frederick, MD, USA) weighing
approximately 300-320 g (age 10-11 weeks) were used for these studies. All housing,
maintenance, and research conditions in this chapter are identical to those described
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previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter Two of
this dissertation.

Assay of lactic acid-stimulated stretching
Behavioral procedure. Six rats that failed to meet the criteria for ICSS within 4
weeks (see below) were used for studies of lactic acid-stimulated stretching as
described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter
Two of this dissertation.
Studies with GW405833 were conducted in two phases. First, a GW405833
dose-effect curve was determined by administering GW405833 (3.2-32 mg/kg or
vehicle) 60 min prior to acid. Second, to assess the role of CB1Rs and CB2Rs in
mediating GW405833 effects, GW405833-induced antinociception in the assay of acidstimulated stretching was evaluated for its sensitivity to antagonism by the CB1R
antagonist rimonabant and the CB2R antagonist SR144528, respectively. For these
studies, rimonabant (1 mg/kg or vehicle) or SR144528 (1 mg/kg or vehicle) was
administered 20 min prior to GW405833 (32 mg/kg), and acid was administered 60 min
after GW405833. These antagonist doses and pretreatment times were based on
previous studies that have demonstrated antagonism of cannabinoid agonist-induced
antinociception with rimonabant (Kwilasz and Negus, 2012) and SR144528 (Hohmann
et al., 2004). All treatments were delivered in randomized order across rats and
separated by at least one week.
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Data Analysis. All methods of data analysis in this chapter are identical to those
described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter
Two of this dissertation.

Assay of intracranial self-stimulation (ICSS)
Surgery. All surgical procedures in this chapter are identical to those described
previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter Two of
this dissertation.
Apparatus. All apparatus and materials used in this chapter are identical to
those described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in
Chapter Two of this dissertation.
Behavioral procedure. After initial shaping of lever press responding, rats were
trained under a continuous reinforcement schedule of brain stimulation using
procedures identical to those described previously (Kwilasz and Negus, 2012;
Rosenberg et al., 2013) and in Chapter Two of this dissertation.
Studies with GW405833 were conducted in three phases. In the first phase, the
effects of GW405833 on ICSS were studied in the absence of the noxious stimulus
(control ICSS). Subjects were placed in their home cages after administration of
GW405833 (1-32 mg/kg or vehicle) and then transferred back to the operant chambers
at the designated times (60, 120, and 240 min) for two consecutive “test” components,
totaling 20 min at each time point. In the second phase, GW405833 effects on ICSS
were studied in the presence of the noxious stimulus (acid-depressed ICSS). Subjects
were administered GW405833 (3.2-32 mg/kg or vehicle) 60 min prior to lactic acid
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(1.8% in a volume of 1 ml/kg), which was administered immediately before two
consecutive “test” components. Lastly, in the third phase, to assess the role of CB1Rs
and CB2Rs in mediating GW405833 effects, GW405833-induced antinociception in the
assay of acid-depressed ICSS was evaluated for its sensitivity to antagonism by the
CB1R antagonist rimonabant and the CB2R antagonist SR144528, respectively. For
these studies, rimonabant (1 mg/kg or vehicle) or SR144528 (1 mg/kg or vehicle) was
administered 20 min prior to GW405833 (32 mg/kg or vehicle), and acid was
administered 60 min after GW405833. All treatments were delivered in randomized
order across rats and separated by at least on week.
Data Analysis. All methods of data analysis in this chapter are identical to those
described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter
Two of this dissertation.

Drugs
Lactic acid was purchased from Sigma Chemical Co. (St. Louis, MO, USA).
GW405833 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Rimonabant and SR144528 were provided by the National Institute on Drug Abuse
Drug Supply Program (Bethesda, MD, USA). Lactic acid was prepared in sterile water.
GW405833 was prepared in a vehicle consisting of 10% ethanol, 10% cremophor
(Sigma), and 90% sterile saline. Rimonabant and SR144528 were prepared in a vehicle
consisting of 5% ethanol, 5% cremophor, and 90% sterile saline. All solutions were
injected intraperitoneally in a volume of 1 ml/kg.
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4.3. Results
Effects of GW405833 on acid-stimulated stretching. Figure 4.1 shows that IP
administration of lactic acid (1.8% in a volume of 1 ml/kg) stimulated approximately 15
stretches after administration of vehicle (gray bar). GW405833 (3.2-32 mg/kg) dosedependently and significantly decreased stretching 60 min after administration. Figure
4.2 shows that the antinociceptive effect of GW405833 in the assay of acid-stimulated
stretching was significantly but only partially antagonized by administration of the CB1R
antagonist rimonabant (1 mg/kg, Fig. 4.2a), but not by the CB2R antagonist SR144528
(1 mg/kg, Fig. 4.2b).
Effects of GW405833 on ICSS in the absence of the noxious stimulus.
During each test session, a “baseline” frequency-rate curve was determined before
testing to permit determination of the Maximum Control Rate (MCR) for that session.
Over the course of the entire study in this group of rats, the average MCR was 51.6 ±
5.1 stimulations/trial and the average baseline total stimulations was 215.2 ± 34.1.
Reinforcement rates during each frequency trial of a session were then expressed as a
percentage of that session’s MCR, and the average baseline frequency-rate curve for all
tests in the control ICSS phase is shown in Figure 4.3a as a gray line. Rats generally
did not respond at frequencies of 56-89 Hz, and reinforcement rates increased across a
frequency range of 89-158 Hz. Maximum reinforcement rates were usually observed at
the highest stimulation frequencies.
When administered 60 min prior to an ICSS session, GW405833 produced
minimal effects on the ICSS frequency-rate curve (Fig. 4.3a). A low dose of 3.2 mg/kg
GW405833 increased ICSS at a single frequency of 100 Hz, whereas an intermediate
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dose of 10 mg/kg GW405833 decreased ICSS at a single frequency of 112 Hz.
GW405833 did not produce any effect on total stimulations at either 60, 120, or 240 min
post-administration (Fig. 4.3b).
Effects of GW405833 on acid-induced depression of ICSS. Figure 4.4 shows
that the same noxious stimulus used in the stretching assay (IP injection of 1.8% lactic
acid in 1 ml/kg) depressed ICSS and that GW405833 (3.2-32 mg/kg) dose-dependently
produced antinociception in the assay of acid-depressed ICSS. Treatment with acid
vehicle had little effect on the frequency-rate curve; however, treatment with 1.8% lactic
acid depressed ICSS, producing a significant rightward shift in the frequency-rate curve
(Fig. 4.4a) and a decrease in total stimulations delivered across all frequencies (gray
bar, Fig. 4.4c). When administered 60 min prior to acid, GW405833 (3.2-32 mg/kg)
produced significant but partial antinociception in the assay of acid-depressed ICSS (32
mg/kg, Figs. 4.4b and 4.4c). A dose of 32 mg/kg GW405833 significantly attenuated
acid-induced depression of ICSS at a single frequency of 112 Hz (Fig. 4.4b).
Additionally, total stimulations delivered across all frequencies after treatment with 32
mg/kg GW405833 were not significantly different from treatment with acid vehicle,
however they were also not different than treatment with acid alone (Fig. 4.4c).
Figure 4.5 shows that the CB1R antagonist rimonabant and the CB2R antagonist
SR144528 failed to reverse GW405833-induced antinociception in the assay of aciddepressed ICSS. Pretreatment with 1 mg/kg rimonabant (Fig. 4.5a) or 1 mg/kg
SR144528 (Fig. 4.5b) had no effect on the antinociceptive effects of 32 mg/kg
GW405833. Furthermore, these doses of rimonabant (Fig. 4.5a) and SR144528 (Fig.
4.5b) produced no effects on acid-induced depression of ICSS alone. Statistical
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analysis did provide some support for a partial attenuation of GW405833-induced
antinociception with rimonabant, insofar as GW405833 + acid was not different than
control, whereas ICSS after rimonabant + GW05833 + acid was depressed relative to
control but also significantly different than acid alone.
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Figure 4.1
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Figure 4.1. GW405833 produced dose-dependent blockade of lactic acid-stimulated
stretching. Figure 4.1 shows the effects of GW405833 (3.2-32 mg/kg) or its vehicle
administered 60 min before acid treatment. Abscissa: dose GW405833 in milligrams per
kilogram. Ordinate: number of stretches observed during a 30 min observation period.
One-way ANOVA indicated a significant main effect of GW405833 treatment
[F(3,12)=7.81; p=0.004]. The asterisk (*) indicates significantly different from vehicle +
acid as determined by Dunnett’s post hoc test, p < 0.05. All bars show mean ± SEM in
five rats.

95
Figure 4.2
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Figure 4.2. GW405833-induced antinociception in the assay of acid-stimulated
stretching is attenuated by rimonabant but not by SR144528. Abscissae: Treatment
conditions. Ordinates: number of stretches observed during a 30 min observation
period. The left panel (a) shows the effect of rimonabant (1 mg/kg or vehicle)
administered 80 min before acid treatment in combination with GW405833 (32 mg/kg or
vehicle) administered 60 min before acid treatment. One-way repeated measures
ANOVA indicated a significant main effect of treatment in panel a [F(3,9)=18.75;
p<0.001]. The right panel (b) shows the effect of SR144528 (1 mg/kg or vehicle)
administered 80 min before acid treatment in combination with GW405833 (32 mg/kg or
vehicle) administered 60 min before acid treatment. One-way repeated measures
ANOVA indicated a significant main effect of treatment in panel b [F(3,9)=32.68;
p<0.001]. Asterisks (*) in all panels indicates significantly different from vehicle + acid,
and the dollar sign ($) in panel a indicates significantly different from GW405833 (32
mg/kg) + acid as determined by Newman-Keuls post hoc test, p < 0.05. All bars show
mean ± SEM in four rats.
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Figure 4.3
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Figure 4.3. GW405833 produced dose-dependent and time-dependent alterations of
intracranial self-stimulation (ICSS) in the absence of a noxious stimulus. The left panel
(a) shows ICSS frequency-rate curves determined 60 min after treatment with
GW405833 (1-32 mg/kg) or its vehicle. Abscissa: frequency of electrical brain
stimulation in hertz (log scale). Ordinate: ICSS rate expressed as percent maximum
control response rate (%MCR). The average baseline ICSS frequency-rate curve for the
entire study in this group of rats is shown by the gray line for comparison, but these data
were not included in statistical analysis. Two-way ANOVA indicated a significant main
effect of frequency [F(9,45)=55.90; p<0.001] and a significant frequency × treatment
interaction [F(27,135)=2.22; p=0.002]. Filled symbols indicate frequencies at which
reinforcement rates after GW405833 treatment were different than rates after
GW405833 vehicle treatment as determined by Holm-Sidak post hoc test, p < 0.05. All
symbols show mean ± SEM in six rats. The right panel (b) shows the total number of
stimulations per component expressed as a percent of baseline stimulations per
component following treatment with GW405833 (1-32 mg/kg) or its vehicle at various
pretreatment times. Abscissa: time following GW405833 or vehicle administration.
Ordinate: percent baseline total number of stimulations per component. Two-way
ANOVA indicated a significant main effect of time [F(2,10)=8.23; p=0.008]. All symbols
show mean ± SEM in six rats.
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Figure 4.4
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Figure 4.4. Lactic acid depresses intracranial self-stimulation (ICSS) and GW405833
produces antinociception in the assay of acid-depressed ICSS. The left panel (a) shows
ICSS frequency-rate curves determined after treatment with GW405833 vehicle 60 min
before lactic acid vehicle or 1.8% lactic acid administration. Abscissa: frequency of
electrical brain stimulation in hertz (log scale). Ordinate: ICSS rate expressed as
percent maximum control response rate (%MCR). Two-way ANOVA indicated a
significant main effect of acid treatment [F(1,4)=24.69; p=0.008] and a significant main
effect of frequency [F(9,36)=23.87; p<0.001]. Filled symbols indicate frequencies at
which reinforcement rates after acid treatment were significantly lower than rates after
acid vehicle treatment as determined by Holm-Sidak post hoc test, p < 0.05. All symbols
show mean ± SEM in five rats. The center panel (b) shows ICSS frequency-rate curves
determined after treatment with GW405833 (3.2-32 mg/kg) or its vehicle 60 min before
acid administration. Abscissa: frequency of electrical brain stimulation in hertz (log
scale). Ordinate: ICSS rate expressed as percent maximum control response rate
(%MCR). Two-way ANOVA indicated a significant main effect of GW405833 treatment
[F(3,12)=3.52; p=0.049], a significant main effect of frequency [F(9,36)=27.47; p<0.001],
and a significant frequency × treatment interaction [F(27,108)=1.59; p=0.049]. Filled
symbols indicate frequencies at which reinforcement rates after GW405833 + acid
treatment were significantly higher than after vehicle + acid treatment as determined by
Holm-Sidak post hoc test, p < 0.05. All symbols show mean ± SEM in five rats. The right
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panel (c) shows the total number of stimulations per component expressed as a percent
of baseline stimulations per component after treatment with GW405833 (3.2-32 mg/kg)
or its vehicle 60 min before administration of acid or its vehicle. Abscissa: dose
GW405833 in milligrams per kilogram. Ordinate: percent baseline total number of
stimulations per component. One-way ANOVA indicated a significant main effect of
treatment [F(4,16)=4.25; p=0.016]. The asterisks (*) indicate significantly different from
GW405833 vehicle + acid vehicle as determined by Newman Keul’s post hoc test, p <
0.05. ICSS after 32 mg/kg GW405833 + acid was not different from either the vehicle +
acid vehicle or the vehicle + acid conditions. All bars show mean ± SEM in five rats.
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Figure 4.5. GW405833-induced antinociception in the assay of acid depressed ICSS is
not antagonized by rimonabant or SR144528. Abscissae: Treatment conditions.
Ordinates: percent baseline total number of stimulations per component. The left panel
(a) shows the effect of rimonabant (1 mg/kg or vehicle) administered 80 min before acid
treatment in combination with GW405833 (32 mg/kg or vehicle) administered 60 min
before acid treatment. One-way repeated measures ANOVA indicated a significant main
effect of treatment in panel a [F(4,20)=19.54; p<0.001]. The right panel (b) shows the
effect of SR144528 (1 mg/kg or vehicle) administered 80 min before acid treatment in
combination with GW405833 (32 mg/kg or vehicle) administered 60 min before acid
treatment. One-way repeated measures ANOVA indicated a significant main effect of
treatment in panel b [F(4,20)=6.90; p=0.001]. Asterisks (*) in all panels indicate
significantly different from vehicle + acid vehicle treatment, and dollar signs ($) in all
panels indicate significantly different from vehicle + acid treatment as determined by
Newman-Keuls post hoc test, p < 0.05. All bars show mean ± SEM in six rats.
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4.4. Discussion
The goal of these studies was to assess the effects of the CB2R agonist
GW405833 in assays of acute pain-stimulated and pain-depressed behavior in rats.
There were three main findings. First, GW405833 produced dose-dependent and
CB1R-mediated but not CB2R-mediated antinociception in the assay of acid-stimulated
stretching. These results demonstrate the potential for GW405833 to produce CB1Rmediated antinociception at higher doses (i.e. 32 mg/kg and higher), and are in
agreement with other studies that have reported GW405833 produces CB1R-like effects
such as behavioral depression and antinociception at high doses (Valenzano et al.,
2005; Whiteside et al., 2005). Second, GW405833 produced no effect on ICSS in the
absence of the noxious stimulus. These results are the first to report on the effects of a
CB2R agonist in an assay of ICSS and show that GW405833 does not produce abuserelated facilitation of ICSS that is characteristic of many other drugs of abuse (Carlezon
and Chartoff, 2007; Bauer et al., 2013). Lastly, GW405833 also produced dosedependent and non CBR-mediated antinociception in the assay of acid-depressed
ICSS, although there was also weak evidence this effect was partially mediated by
CB1Rs. Collectively, these results show that GW405833 produces antinociception in
both assays of pain-stimulated and pain-depressed behavior, but through non CB2Rmediated mechanisms. Further research is necessary to determine the other
mechanisms mediating GW405833-induced antinociception in assays of acute painstimulated and pain-depressed. Lastly, these results question the importance of CB2R
activation for the treatment of acute pain.
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CHAPTER FIVE
Effects of THC on acute and repeated LPS-induced stimulation
of mechanical allodynia and depression of ICSS.

5.1. Introduction
Marijuana has been used for centuries to treat pain, and CBR agonists produce
antinociception in many preclinical assays of pain (Rice, 2006; Karst et al., 2010). CBR
agonists have also been shown to produce anti-inflammatory effects in many preclinical
assays, and this effect is thought to be at least partially responsible for the
antinociceptive effects of CBR agonists in these studies (Croxford and Yamamura,
2005; Burstein and Zurier, 2009; Stein and Machelska, 2011). Specifically, CBR
agonists have been shown to decrease physiological increases in pro-inflammatoryrelated molecules, such as cytokines, after treatment with an inflammatory challenge,
such as LPS (Puffenbarger et al., 2000; Roche et al., 2006). In clinical studies, CBR
agonists have been shown to have some efficacy to treat inflammatory-related pain
(Blake et al., 2006), and have also been approved to treat multiple sclerosis-related
muscle spasticity and associated pain and in several countries worldwide (Leussink et
al., 2012). The analgesic effects of CBR agonists in these clinical pathologies may also
be related to their anti-inflammatory properties.
There were two main goals in this study. First, we sought to evaluate the effects
of chronic and acute inflammatory challenges (i.e. repeated or acute IP LPS,
respectively) on pain-related stimulation of mechanical allodynia and pain-related
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depression of behavior. Administration of LPS or direct administration of proinflammatory cytokines has previously been shown to produce mechanical allodynia in a
Von Frey paw-withdrawal procedure and hyperalgesia in a warm water tail-flick
procedure (Watkins et al., 1994; Cahill et al., 1998). Furthermore, other studies have
shown that LPS or pro-inflammatory cytokine administration produces inflammationrelated decreases in behavior such as ICSS (Anisman et al., 1996; Anisman et al.,
1998; Borowski et al., 1998; Barr et al., 2003; van Heesch et al., 2013), feeding (Kubera
et al., 2013), and social interaction (Konsman et al., 2008). The second goal of this
study was to assess the effects of the prototype cannabinoid agonist, THC, on LPSstimulated mechanical allodynia (assay of pain-stimulated behavior) and LPS-induced
depression of ICSS (assay of pain-depressed behavior), as cannabinoid agonists have
been shown to produce robust anti-inflammatory effects in many preclinical studies
(Croxford and Yamamura, 2005; Valenzano et al., 2005; Whiteside et al., 2005; Burstein
and Zurier, 2009) and may also be effective in several clinical chronic inflammatory
pain-related disorders (i.e. rheumatoid arthritis and multiple sclerosis) (Blake et al.,
2006; Leussink et al., 2012). We have previously used assays of pain-stimulated and
pain-depressed behavior to assess the effects of opioids, nonsteroidal anti-inflammatory
drugs, and other drug classes (Pereira Do Carmo et al., 2009; Negus et al., 2010b;
Kwilasz and Negus, 2012; Negus et al., 2012; Rosenberg et al., 2013). Specifically, we
have shown that the mixed CB1R/CB2R agonists THC and CP55940 failed to produce
antinociception on acute pain-induced depression of behavior (Kwilasz and Negus,
2012) elicited by IP lactic acid administration, a finding concordant with the poor clinical
efficacy of CBR agonists as analgesics against acute pain in humans (Raft et al., 1977;
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Rice, 2006; Karst et al., 2010; Kraft, 2012). Chapters three and four of this dissertation
also show that the FAAH inhibitor URB597 and the CB2R agonist GW405833 produce
non-CBR-mediated antinociception in the assay of pain-depressed behavior. Taken
together, these data suggest that assays of pain-depressed behavior may be useful for
the assessment of candidate cannabinoid analgesics, and furthermore may provide
insight into new mechanisms of cannabinoid-mediated antinociception. Insofar as CBR
agonists produce anti-inflammatory effects and may be effective to treat several clinical
inflammatory pain-related disorders (Blake et al., 2006; Leussink et al., 2012), we
predicted that a CBR agonist such as THC might be more effective against an
inflammatory noxious stimulus such as IP LPS versus a chemically-induced noxious
stimulus such as IP acid. Body temperature was also assessed as a physiological
indicator of LPS exposure.

5.2. Methods
Subjects
Twenty-eight male Sprague-Dawley rats (Harlan, Frederick, MD, USA) weighing
approximately 300-320 g (age 10-11 weeks) were used for these studies. All housing,
maintenance, and research conditions in this chapter are identical to those described
previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter Two of
this dissertation.
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Assay of LPS-induced changes in body temperature
Behavioral procedure. Eighteen rats were used for studies of LPS-induced
changes in body temperature. During test sessions, rats were wrapped in a 2 ft. x 3 ft.
length of surgical drape and held firmly horizontally against the chest of the
experimenter. A 2 mm diameter wire probe attached to a Thermometer (VWR
International; Radnor, PA) was inserted into the subject’s rectum to a marked line that
indicated approximately 3.5 cm from the tip of the probe and was held in place for 6
seconds or until a stable temperature was obtained. Rats were tested for body
temperatures immediately after determining mechanical thresholds in the assay of LPSstimulated mechanical allodynia as described below.
To assess the effect of THC on acute LPS-induced changes in body
temperature, THC (0.32-1 mg/kg or vehicle) was administered 90 min after LPS or
saline. Body temperatures were determined immediately prior to THC administration
(LPS/saline baseline), and then 30 and 100 min thereafter. Tests were conducted
weekly, and animals received LPS and saline once every two weeks, alternating LPS
and saline treatments each week for a total of 6 weeks. THC was delivered in LatinSquare dose order and doses were separated by one week.
Data Analysis. Drug effects on LPS-induced changes in body temperature were
evaluated by repeated measures two-way analysis of variance (ANOVA). A significant
ANOVA was followed by Holm-Sidak post hoc test, and the criterion for significance was
set at p < 0.05.
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Assay of LPS-stimulated mechanical allodynia
Behavioral procedure. Twenty-three rats were used for studies of LPSstimulated mechanical allodynia. During test sessions, rats were placed in an elevated,
custom-built chamber composed of acrylic walls and a wire mesh floor (15 cm high x 41
cm deep x 91 cm across) to permit access to the plantar surfaced of the right rear paw
from below. The up-and-down method was used to determine mechanical thresholds
(Chaplan et al., 1994). Rats were habituated in the chamber for at least 15 min prior to
testing.
Studies with LPS were conducted in two phases. First, the effect of chronic LPS
administration on mechanical thresholds was determined by administering LPS (0.1
mg/kg) 30 min and 100 min before mechanical threshold determination for 7
consecutive days. Saline was also administered for three days prior to LPS and data
from these days were averaged to determine a saline baseline. Rats in the first phase
had intracranial ICSS implants and were also subjects in ICSS studies that were
conducted immediately after the mechanical threshold determination. Second, in a
separate group of rats without intracranial ICSS implants, to assess the effect of THC
on acute LPS-stimulated mechanical allodynia, THC (0.32-1 mg/kg or vehicle) was
administered 90 min after LPS or saline. Mechanical thresholds were determined
immediately prior to THC administration (baseline), and then 30 and 100 min thereafter.
Tests were conducted weekly, and animals received LPS and saline once every two
weeks, alternating LPS and saline treatments each week for a total of 6 weeks. THC
was delivered in Latin-Square dose order and doses were separated by one week.
Animals in phase two tested in the mechanical allodynia procedure were also tested for
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LPS-induced changes in body temperature as described above immediately following
determination of mechanical thresholds.
Data Analysis. Drug effects on LPS-stimulated mechanical were evaluated by
repeated measures one-way or two-way analysis of variance (ANOVA). A significant
ANOVA was followed by Dunnett’s (one-way) or Holm-Sidak (two-way) post hoc test,
and the criterion for significance was set at p < 0.05. In phase one, the saline baseline
(average of 3 days prior to LPS injection) served as the baseline for the rest of the
study. In phase two, baselines were determined before LPS/saline injection on each test
day.

Assay of intracranial self-stimulation (ICSS)
Surgery. All surgical procedures in this chapter are identical to those described
previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in Chapter Two of
this dissertation.
Apparatus. All apparatus and materials used in this chapter are identical to
those described previously (Kwilasz and Negus, 2012; Rosenberg et al., 2013) and in
Chapter Two of this dissertation.
Behavioral procedure. After initial shaping of lever press responding, rats were
trained under a continuous reinforcement schedule of brain stimulation using
procedures identical to those described previously (Kwilasz and Negus, 2012;
Rosenberg et al., 2013) and in Chapter Two of this dissertation.
Studies with LPS were conducted in two phases. In phase one, the effects of
chronic LPS on ICSS were studied. In this phase, LPS (0.1 mg/kg) was administered
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consecutively for seven days 30 min and 100 min before the ICSS session. Subjects
were placed in the chamber to determine mechanical thresholds after administration of
LPS (0.1 mg/kg) and then transferred back and forth to the operant chambers at the
designated times (30 and 100 min) for three consecutive “test” components, totaling 30
min at each time point. Saline was also administered for three days prior to LPS and
data from these days were averaged to determine a saline baseline. In the second
phase, the effects of THC on acute LPS-induced depression of ICSS were studied. In
this phase, LPS (0.1 mg/kg or saline) was administered immediately after removing the
subjects from the operant chamber after the third baseline component. Subjects were
placed in their home cages after administration of LPS and then transferred back to the
operant chambers after 90 min for two consecutive “test” components, for a total of 20
min. This initial test was used to determine the baseline effect of LPS. Immediately after
determination of this baseline, THC (0.32-1 mg/kg or vehicle) was administered and
subjects were placed in their home cages and transferred back to the operant chambers
at the designated times (30 and 100 min) for two consecutive “test” components,
totaling 20 min at each time point. Tests were conducted weekly, and animals received
LPS and saline once every two weeks, alternating LPS and saline treatments each
week for a total of 6 weeks. THC was delivered in Latin-Square dose order and doses
were separated by one week.
Data Analysis. The primary dependent variable in this ICSS procedure was the
total number of stimulations per component, which was calculated as the sum of
stimulations delivered across all 10 frequency-trials of each component. Test data were
then normalized to individual baseline data using the equation Percent Baseline Total
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Stimulations per Component = (Mean Total Stimulations per Test Component ÷ Mean
Total Stimulations per Baseline Component) x 100. Data were then averaged across
rats in each experimental condition and compared by repeated measures one-way
ANOVA or two-way ANOVA where appropriate. A significant one-way ANOVA was
followed by Dunnett’s post hoc test, a significant two-way ANOVA was followed by
Holm-Sidak post hoc test, and the criterion for significance was set at p < 0.05. In phase
one, the saline baseline (average of 3 days prior to LPS injection) served as the
baseline for the rest of the study, and subsequent data collected with LPS were
normalized to this baseline. In phase two, baselines were determined before LPS/saline
injection on each test day, and data for each test day were normalized to its respective
baseline.

Drugs
LPS was purchased from Sigma Chemical Co. (St. Louis, MO). THC was
provided by the National Institute on Drug Abuse Drug Supply Program (Bethesda, MD).
LPS was prepared in sterile saline. THC was prepared in a vehicle consisting of
ethanol, cremophor (Sigma), and sterile saline in a ratio of 1:1:18, respectively. All
solutions were injected intraperitoneally in a volume of 1 ml/kg.

5.3. Results
Effects LPS and THC on body temperature. Figure 5.2a shows that acute IP
administration of LPS (0.1 mg/kg) induced treatment-dependent hypothermia 90 min
after administration. This effect was treatment dependent, as subsequent treatments
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with LPS failed to induce hypothermia (Figure 5.2a). Figure 5.3 (panels a and d) show
that administration of THC (0.32-1 mg/kg or vehicle) did not significantly alter body
temperature alone or in combination with LPS at either 30 min (Fig. 5.3a) or 100 min
(Fig. 5.3d) post-administration, and both Figs. 5.3a and 5.3d further illustrate the
variable and weak effects of LPS on body temperature.
Effects of THC on LPS-stimulated mechanical allodynia. Figure 5.1a shows
that chronic administration of LPS (0.1 mg/kg) produced a significant decrease in
mechanical thresholds for the first two consecutive days at 30 min post-administration.
This effect was no longer seen on days 3-7 of LPS treatment, however. Moreover, this
same regimen of LPS failed to significantly decrease mechanical thresholds on any day
at 100 min post-administration (Fig 5.1c). Figure 5.2b shows that acute IP
administration of LPS (0.1 mg/kg) did not produce a significant effect on mechanical
thresholds 90 min after administration on any of the three times it was tested. Figure 5.3
shows that administration of THC (0.32-1 mg/kg or vehicle) did not significantly alter
mechanical thresholds alone or in combination with LPS at either 30 min (Fig. 5.3b) or
100 min (Fig. 5.3e) post-administration.
Effects of THC on LPS-induced depression of ICSS. Figure 5.1 (panels b and
d) show that chronic administration of LPS (0.1 mg/kg) produced a time-dependent
decrease in total stimulations of ICSS delivered across all frequencies. LPS significantly
decreased ICSS at 30 min post-administration on the second day of chronic treatment
(Fig. 5.1b), whereas at 100 min post-administration, ICSS was significantly decreased
on days 1, 2, and 4 of chronic LPS treatment (Fig. 5.1d). Figure 5.2c shows that acute
IP administration of LPS (0.1 mg/kg) produced variable and weak decreases in total
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stimulations of ICSS delivered across all frequencies compared to administration of IP
lactic acid used in previous chapters. Specifically, acute LPS treatment significantly
decreased total stimulations of ICSS after the first and third administration, but not after
the second administration (2-week washout between LPS treatments) (Fig. 5.2c). Figure
5.3 shows that administration of THC (0.32-1 mg/kg or vehicle) did not significantly alter
LPS-induced depression of ICSS at either 30 min (Fig. 5.3c) or 100 min (Fig. 5.3f) postadministration.
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Figure 5.1
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Figure 5.1. Chronic LPS produces a treatment- and time-dependent decrease in
mechanical thresholds and ICSS. Figure 5.1a shows the effect of LPS (0.1 mg/kg) or
saline administered 30 min before mechanical threshold determination. Abscissa (all
panels): day of LPS treatment. Ordinate (panels a and c): Log mechanical threshold in
grams. One-way ANOVA indicated a significant main effect of LPS treatment
[F(7,21)=3.92; p=0.007]. Figure 5.1c shows the effect of LPS (0.1 mg/kg) or saline
administered 100 min before mechanical threshold determination. One-way ANOVA
indicated a significant main effect of LPS treatment [F(7,21)=2.69; p=0.038]. Figure 5.1b
shows the effect of LPS (0.1 mg/kg) or saline administered 30 min before ICSS.

112
Ordinate (panels b and d): percent baseline total number of stimulations per component.
One-way ANOVA indicated a significant main effect of LPS treatment [F(7,28)=3.73;
p=0.005]. Figure 5.1d shows the effect of LPS (0.1 mg/kg) or saline administered 100
min before ICSS. One-way ANOVA indicated a significant main effect of LPS treatment
[F(7,28)=10.22; p<0.001]. Filled symbols indicate significantly different from saline
treatment as determined by Dunnett’s post hoc test, p < 0.05. All bars show mean ±
SEM in five rats.
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Figure 5.2
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Figure 5.2. Acute LPS administration produces unreliable and treatment-dependent
effects on body temperature, mechanical thresholds, and ICSS. Figure 5.2a shows the
effect of LPS (0.1 mg/kg) or saline administered 90 min before determination of body
temperatures. Abscissa (all panels): Number of times treated with LPS or saline.
Ordinate: Change in body temperature from pre-LPS/saline baseline in degrees Celsius.
Two-way ANOVA indicated a significant main effect of LPS treatment [F(1,17)=7.91;
p=0.012], a significant main effect of times treated [F(2,34)=16.14; p<0.001], and a
significant treatment x times treated interaction [F(2,34)=9.13; p<0.001]. All bars show
mean ± SEM in 18 rats. 5.2b shows the effect of LPS (0.1 mg/kg) or saline administered
90 min before determination of mechanical thresholds. Ordinate: Log mechanical
threshold in grams. Two-way ANOVA indicated a significant main effect of times treated
[F(2,34)=4.48; p=0.019]. All bars show mean ± SEM in 18 rats. Figure 5.2c shows the
effect of LPS (0.1 mg/kg) or saline administered 90 min before determination of ICSS.
Ordinate: percent baseline total number of stimulations per component. Two-way
ANOVA indicated a significant main effect of LPS treatment [F(1,4)=12,16; p=0.025]
and a significant treatment x times treated interaction [F(2,8)=5.27; p<0.035]. All bars
show mean ± SEM in six rats. Asterisks (*) in all panels indicate significantly different
than respective saline control bar as determined by Holm-Sidak post hoc test, p < 0.05.
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Figure 5.3
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Figure 5.3. THC administration does not alter acute LPS-induced effects on body
temperature, mechanical thresholds, and ICSS. 5.3a shows the effect of THC (0.32-1
mg/kg or vehicle) administered 30 min after LPS or saline on body temperature.
Abscissa (all panels): Dose THC in milligrams per kilogram. Ordinate (panels a and d):
Change in body temperature from pre-LPS/saline baseline in degrees Celsius. Two-way
ANOVA indicated a significant main effect of LPS treatment [F(1,5)=13.00; p=0.015].
Figure 5.3d shows the effect of THC (0.32-1 mg/kg or vehicle) administered 100 min
after LPS or saline on body temperature. There was no effect of LPS or THC on body
temperature at this time point as indicated by two-way ANOVA. Figure 5.3 shows the
effect of THC (0.32-1 mg/kg or vehicle) administered 30 min (Fig. 5.3b) and 100 min
(Fig. 5.3e) after LPS or saline on mechanical thresholds. Ordinate (panels b and e): Log
mechanical threshold in grams. There was no effect of LPS or THC on mechanical
thresholds at either time point. All bars in panels a-d show mean ± SEM in 18 rats.
Figure 5.3c shows the effect of THC (0.32-1 mg/kg or vehicle) administered 30 min after
LPS or saline on LPS-depressed ICSS. Ordinate (panels c and f): percent baseline total
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number of stimulations per component. Two-way ANOVA indicated a significant main
effect of LPS treatment [F(1,4)=25.01; p=0.008]. Figure 5.3f shows the effect of THC
(0.32-1 mg/kg or vehicle) administered 100 min after LPS or saline on LPS-depressed
ICSS. Two-way ANOVA indicated a significant main effect of LPS treatment
[F(1,4)=17.54; p=0.014].
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5.4. Discussion
The goal of these studies was to assess the effects of THC in assays of LPSstimulated and LPS-depressed behavior. Body temperature was also included as a
physiological marker of LPS effects. There were four main findings. First, chronic LPS
administration produced treatment- and time-dependent stimulation of mechanical
allodynia as well as treatment- and time-dependent decreases in ICSS. In general,
however, these effects of LPS were transient and unreliable. Second, acute LPS
administration produced no effect on mechanical thresholds, and as with chronic
administration, also produced transient and unreliable decreases in ICSS. The
discrepancy between acute and chronic LPS administration in the assay of mechanical
allodynia may be due to a number of dose, time, or subject-related variables. There is
no literature, however, that supports this profile of effects of LPS on mechanical
thresholds. Furthermore, some literature suggests an initial inflammatory insult may be
necessary to produce (or “prime”) LPS-stimulated mechanical allodynia (Cahill et al.,
1998; Hains et al., 2010). In this regard, animals studied with THC in the assays of
mechanical allodynia and body temperature did not have intracranial implants, which
also may have influenced behavioral responses to LPS administration, as the
intracranial surgery could have served at least as a “priming” inflammatory insult. Third,
acute LPS produced a reliable hypothermic effect after the first administration, but this
effect was absent after the second and third LPS administrations. LPS has previously
been shown to produce both hyperthermic effects in rats (Klir et al., 1993, unpublished
observations); however, it has only been shown to produce hypothermic effects at
higher doses in rats (Steiner et al., 2011; Al-Saffar et al., 2013). The dose chosen for
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LPS was 0.1 mg/kg, which is moderately high compared to other studies. Thus although
these data were not predicted, they also were not completely unexpected. Lastly, THC
administration did not alter the rather weak effects of LPS on body temperature,
mechanical thresholds, and ICSS. Taken together, these results suggest that LPS was
a poor noxious stimulus in this set of experiments compared to IP lactic acid used in
previous chapters. Future studies would benefit from a more extensive manipulation of
dose-, time-, and subject-related variables in regard to LPS administration, and/or
assessment of other inflammatory-related noxious stimuli.
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CHAPTER SIX
Discussion

6.1. Summary
The experiments described in this dissertation evaluated the antinociceptive
effects of cannabinoid receptor agonists and of FAAH inhibitors in preclinical assays of
pain-stimulated and pain-depressed behaviors in rats. In chapters 2-4, an IP injection of
dilute lactic acid served as the noxious stimulus to model acute pain. All cannabinoids
tested produced CB1R-mediated antinociception in the assay of acid-stimulated
stretching with the exception of PF3845, which for unknown reasons produced
pronociception. In contrast, cannabinoids produced distinct effects in assays of aciddepressed behavior. The mixed-action CB1R/CB2R agonists THC and CP55940 failed
to produce antinociception in assays of pain-depressed behavior, whereas the FAAH
inhibitor URB597 and the CB2R agonist GW405833 both produced submaximal though
statistically significant antinociception. Intriguingly, the effects of both of URB597 and
GW405833 were not mediated by CB1Rs or CB2Rs. Moreover the other FAAH inhibitor,
PF3845, failed to produce antinociception in the assay of acid-depressed ICSS; a
finding concordant with its lack of effect in the assay of pain-stimulated behavior, but
discrepant with the antinociceptive effects of the other FAAH inhibitor URB597 in the
same assays. Taken together, the results with URB597 and GW40583 suggest
alternative non-cannabinoid mechanisms may mediate the antinociceptive effects of
these two compounds in assays of pain-depressed behavior. In chapter 5, we also
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attempted to model more chronic inflammatory-related pain through acute/repeated IP
injection of LPS and subsequent assessment of mechanical allodynia and depression of
ICSS. LPS produced weak and unreliable pronociceptive effects in assays of both LPSstimulated mechanical allodynia or LPS-depressed ICSS, and these weak effects of
LPS made it difficult to assess the effects of cannabinoids on LPS-induced
pronociceptive behavior. THC was nevertheless tested in these assays but did not show
any indication that it altered these weak effects of LPS. These results provide weak
evidence that THC may be ineffective against LPS-stimulated mechanical allodynia and
LPS-depressed ICSS; however, further studies are needed with a more reliable chronic
inflammatory-related noxious stimulus to fully determine the effects of cannabinoids in
assays of chronic inflammatory pain-depressed behavior.

6.2. Effects of the mixed CB1R/CB2R agonists THC and CP55940
on acute pain-stimulated and pain-depressed behavior.
Cannabinoid agonist effects on pain-stimulated behavior. In assays of painstimulated behavior, delivery of a noxious stimulus increases the rate or intensity of the
target behavior, and drug-induced antinociception is inferred from drug-induced
decreases in the target behavior (Negus et al., 2010a). In the present study, acid
stimulated a stretching response in rats, and THC and CP55940 produced
antinociception insofar as they decreased acid-stimulated stretching. The
antinociceptive effects of THC and CP55940 in the present study agree with a large
literature showing that cannabinoid agonists produce antinociception in nearly all
assays of pain-stimulated behavior (for recent reviews, see Rice, 2006; Karst et al.,
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2010). For example, previous studies in rodents have shown that cannabinoid agonists
decreased stretching elicited by IP acid administration (Sofia et al., 1975; Anikwue et
al., 2002; Booker et al., 2009), first and second phases of nociceptive behavior elicited
by intraplantar formalin injection (Finn et al., 2004; Khodayar et al., 2006), tail-flick/pawwithdrawal responses elicited by noxious heat (Lichtman and Martin, 1991; De Vry et
al., 2004; Wiley et al., 2007), and hypersensitive withdrawal responses elicited by
thermal/mechanical stimuli in inflammatory or neuropathic pain models (Cheng and
Hitchcock, 2007; Elikkottil et al., 2009; Sain et al., 2009). As in the present study,
cannabinoid antinociception is often shown to be dose and/or time dependent, and
sensitivity to rimonabant antagonism or genetic knockout of cannabinoid 1 receptors
has been interpreted as evidence of cannabinoid 1 receptor mediation (Monory et al.,
2007; Booker et al., 2009). It is generally appreciated that nonselective behavioral
depression may confound measures of cannabinoid antinociception in assays of painstimulated behavior (De Vry et al., 2004; Finn et al., 2004), and in the present study,
THC and CP55940 produced evidence of nonselective behavioral depression insofar as
they decreased ICSS in the absence of pain. However, THC-induced depression of
acid-stimulated stretching was longer lasting than THC-induced depression of control
ICSS. Furthermore, chronic THC administration produced complete tolerance to THCinduced depression of control ICSS, while only partial tolerance developed to THCinduced depression of acid-stimulated stretching. Lastly, CP55940 produced
antinociception in the assay of acid-stimulated stretching at doses that produced no
effect on control ICSS. These findings provide evidence for a selective antinociceptive
effect of cannabinoids in assays of pain-stimulated behavior. Similarly, other studies of
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pain-stimulated behavior on THC and CP55940 have found comparable dose selectivity
for antinociception versus nonselective behavioral depression (Fox et al., 2001; Booker
et al., 2009). Overall, the robust and reliable antinociceptive effects of cannabinoid
agonists in preclinical assays of pain-stimulated behavior have encouraged
development of cannabinoids as candidate analgesics.
Cannabinoid agonist effects on pain-depressed behavior. In assays of paindepressed behavior, delivery of a noxious stimulus decreases the rate or intensity of the
target behavior, and drug-induced antinociception is inferred from drug-induced
increases in the target behavior (Negus et al., 2010a). In the present study, acidinduced depression of ICSS and of feeding served as assays of pain-depressed
behavior, and in these assays, THC and CP55940 failed to produce antinociception.
Rather, THC and CP55940 only exacerbated acid-induced depression of ICSS and
were ineffective in the assay of acid-depressed-feeding. This lack of cannabinoid
antinociception cannot be attributed to a lack of assay sensitivity. In the present study
and in a previous study (Negus et al., 2011), the NSAID ketoprofen blocked acidstimulated stretching and acid-induced depression of ICSS and feeding, and these data
agree with the clinical efficacy of ketoprofen for treatment of acute pain in animals
(Flecknell, 2009) and humans (Sarzi-Puttini et al., 2010). Similarly, the mu opioid
receptor agonist and clinically effective analgesic morphine also blocked acid-stimulated
stretching and acid-induced depression of ICSS in rats (Pereira Do Carmo et al., 2009;
Negus et al., 2010b) and acid-induced depression of feeding in mice (Stevenson et al.,
2006). Both NSAID and mu-opioid analgesics have also been shown to block other
examples of pain-depressed behavior including acid-induced depression of locomotion
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and wheel running in mice (Stevenson et al., 2009; Miller et al., 2011), laparotomyinduced depression of locomotion and food-maintained operant responding in rats
(Martin et al., 2007), and depression of locomotion and wheel running induced by
bilateral inflammation of the knee joints by complete Freund’s adjuvant in rats (Matson
et al., 2007; Cobos et al., 2012). Taken together, these results suggest that cannabinoid
agonist effects on pain-depressed behavior are opposite to those produced by clinically
effective NSAID and opioid analgesics.
Determinants of the poor efficacy of cannabinoids in assays of pain-depressed
behavior remain to be understood. However, three points warrant mention. First,
cannabinoids can produce general behavioral depressant effects manifested in this
study as decreases in control ICSS, and such general behavioral depressant effects
could obscure expression of antinociception in assays of pain-depressed behavior
(Negus et al., 2010a). However, several findings argue against a major influence of this
factor. For example, THC/CP55940 failed to block acid-induced depression of ICSS
even at times/doses that did not decrease control ICSS but did block acid-stimulated
stretching. Moreover, in contrast to previous results with a delta opioid receptor agonist
(Negus et al., 2012), chronic administration of THC did not unmask antinociceptive
effects of THC in the assay of acid-depressed ICSS, despite producing complete
tolerance to THC-induced rate-decreasing effects on control ICSS and only partial
tolerance to THC-induced antinociception in the assay of acid-stimulated stretching.
Lastly, THC failed to block pain-related depression of feeding at a dose that did
attenuate satiation-related depression of feeding in this study and that stimulated
feeding by rats in other studies (Williams et al., 1998; Jarbe and DiPatrizio, 2005).
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Consequently, just as nonselective behavioral depression could not account entirely for
the apparent presence of cannabinoid antinociception in the assay of pain-stimulated
behavior, it also cannot account entirely for the absence of cannabinoid antinociception
in the assays of pain-depressed behavior.
Second, the neural circuits that mediate acid-induced stimulation of stretching
and depression of ICSS are incompletely mapped but may be dissociable (Willis, 2009),
and the present results provide support for this contention. For example, noxious stimuli
activate both serial and parallel spinal and supraspinal pathways, and different neural
circuits have been associated with different components of pain (e.g. sensory vs.
affective components of pain) (Price, 2002; Borsook and Becerra, 2011). Results of the
present study suggest that THC and other cannabinoids may be more effective in
modulating neural circuits that mediate acid-induced stimulation of stretching than those
mediating acid-induced depression of ICSS.
Lastly, the present study evaluated effects of systemic cannabinoid
administration on pain-related behaviors produced by an acute chemical noxious
stimulus delivered to the abdominal cavity, and poor cannabinoid antinociception may
be related to these or other experimental variables. To expand the scope of these data,
we assessed the efficacy of other cannabinoid drugs (i.e. inhibitors of endocannabinoid
hydrolysis and agonists selective for cannabinoid 2 receptors) to produce
antinociception in assays acute acid-stimulated stretching and acid-depressed ICSS in
Chapters Three and Four of this dissertation. We furthermore examined the effects of
THC on LPS-stimulated mechanical allodynia and LPS-depressed ICSS in Chapter Five
of this dissertation, to assess the efficacy of a cannabinoid receptor agonist against a
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more inflammatory-related pain state. Other studies would also benefit from assessing
other modalities of noxious stimuli, or by noxious stimulation of other parts of the body,
as well as by administration of cannabinoids via other routes of administration (e.g.
intraplantar, intravenous, inhalation, etc.). However, the present results from this
chapter demonstrate the potential for diametrically opposite effects of cannabinoid
receptor agonists on pain-stimulated and pain-depressed behaviors elicited by the same
noxious stimulus. Moreover, these results distinguish these cannabinoids from clinically
effective analgesics and suggest that cannabinoid antinociception in assays of acute
pain-stimulated behavior cannot be attributed to a simple and selective blockade of
sensitivity to noxious stimuli.
Abuse-related effects of mixed CB1/CB2R cannabinoid agonists. In control
experiments for this study, cannabinoid effects on ICSS were evaluated in the absence
of the acid noxious stimulus. Drug-induced facilitation of ICSS under these conditions is
often interpreted as an abuse-related effect (Carlezon and Chartoff, 2007), but THC and
CP55940 produced only decreases in ICSS. These results are consistent with previous
studies showing only rate-decreasing effects of cannabinoid agonists on ICSS (Vlachou
et al., 2005; Vlachou et al., 2007), although other studies have found weak facilitation of
ICSS by THC under certain conditions (Gardner et al., 1988; Lepore et al., 1996). THC
and other cannabinoid agonists also often fail to produce place conditioning as well as
reinforcing effects in assays of cannabinoid drug self-administration (see Panagis et al.,
2008 for review). Taken together, these findings suggest that THC and related
cannabinoids often fail to produce abuse-related facilitation of ICSS under conditions
that are sensitive to facilitation by other classes of abused drugs.
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6.3. Effects of the FAAH inhibitors URB597 and PF3845 on acute pain-stimulated
and pain-depressed behavior.
FAAH inhibitor effects on pain-stimulated behavior. Chapter 3 described effects
of the FAAH inhibitors URB597 and PF3845 in the same assays of acid-stimulated
stretching and acid-depressed ICSS that were used in testing with THC and CP55940.
URB597 produced dose-dependent and CB1R-mediated antinociception in the assay of
acid-stimulated stretching insofar as it decreased this stretching behavior at 1 h and 4 h
after administration. The antinociceptive effects of URB597 are in agreement with
previous studies showing that URB597 produces dose-dependent and CB1R-mediated
antinociception in other preclinical assays of pain-stimulated behavior, such as
stretching elicited by intraperitoneal acetic acid administration (Naidu et al., 2009;
Clapper et al., 2010; Miller et al., 2012), first and second phases of nociceptive behavior
elicited by intraplantar formalin injection (Hasanein et al., 2009), tail-flick responses
elicited by noxious heat (Hasanein et al., 2009), and hypersensitive withdrawal
responses elicited by thermal/mechanical stimuli in inflammatory or neuropathic pain
models (Jayamanne et al., 2006; Jhaveri et al., 2006; Guindon et al., 2013). These
results thus add to a growing body of literature that supports the antinociceptive effects
of URB597 in various preclinical models of pain-stimulated behavior.
In contrast to the results with URB597, PF3845 decreased the mean number of
acid-stimulated stretches when tested 1 h after PF3845 administration, but this effect
did not achieve statistical significance. Moreover, PF3845 produced a pronociceptive
increase in acid-stimulated stretching 4 h post-administration. These effects of PF3845
contrast not only with the present results with URB597, but also with previous studies
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reporting antinociceptive effects of PF3845 in other preclinical assays of pain-stimulated
behavior where PF3845 was tested anywhere from 2-8 h post-administration (Ahn et al.,
2009; Long et al., 2009; Kinsey et al., 2010; Booker et al., 2012; Ghosh et al., 2012).
There are at least two possible reasons for this discrepancy. First, expression of
PF3845 antinociception may be influenced by experimental variables such as the type
of noxious stimulus, the time tested after administration, and species of subject. This is
the first study to examine effects of PF3845 on acid-stimulated stretching in rats, and
previous studies have been conducted primarily in mice using chronic inflammatory or
neuropathic pain models (Sagar et al., 2010a; Sagar et al., 2010b; Guindon et al.,
2013). Second, drugs that produce nonselective behavioral depression can produce
false-positive antinociception in assays of pain-stimulated behavior by impairing the
subject’s ability to perform in the assay (Negus et al., 2010a). For example, in this
study, both URB597 and PF3845 significantly depressed control ICSS at doses and
early treatment times similar to those at which they produced their greatest reductions in
acid-stimulated stretching. Moreover, URB597 produced greater decreases than
PF3845 both in control ICSS and in acid-stimulated stretching. Lastly, the present data
with URB597 are consistent with previous studies showing that URB597 at high doses
can decrease locomotor activity (Lee et al., 2006) and ICSS (Vlachou et al., 2006).
Taken together, these results suggest that, in assays of pain-stimulated behavior, any
apparent dissociation in antinociceptive effects of URB597 and PF3845 at short posttreatment times could be mediated in part by a dissociation in their efficacies to produce
nonselective behavioral depression. However, this interpretation does not account for
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the antinociceptive effect of URB597 and pronociceptive effect of PF3845 4 h postadministration, because neither URB597 nor PF3845 altered control ICSS at this time.
FAAH inhibitor effects on pain-depressed behavior. URB597 partially attenuated
acid-induced depression of ICSS in the present study, and these data agree with a
previous study that reported partial efficacy of URB597 in assays of acid-depressed
wheel-running and acid-depressed feeding in mice (Miller et al., 2012). Moreover, the
present finding that URB597 produced antinociception in assays of both acid-stimulated
stretching and acid-depressed ICSS without altering control ICSS at the 4 h test time
further suggests that URB597 effects included analgesic attenuation of sensitivity to the
noxious stimulus rather than (or in addition to) non-selective motor effects. This profile
supports further consideration of URB597 as a candidate analgesic. Intriguingly, though,
URB597 antinociception in the assay of acid-depressed ICSS was not blocked by the
CB1R antagonist rimonabant, suggesting that URB597 effects in this assay were not
mediated by CB1 receptors. This contrasts with findings in the assay of acid-stimulated
stretching (present study) and with rimonabant antagonism of URB597 antinociception
in assays of acid-depressed behavior in mice (Miller et al., 2012). Taken together, these
findings suggest a potential for URB597 to produce antinociception via both CB1Rmediated and non-CB1R-mediated mechanisms. The present study evaluated a
potential role of CB2Rs and PPAR-α as two possible non-CB1R mechanisms, but
results did not support the role of either CB2Rs or PPAR-α in mediating URB597induced antinociception in the assay of acid-depressed ICSS. Other possible non-CB1R
mechanisms might include effects mediated by TRPV1 ion channels (Maione et al.,
2006), abnormal-cannabidiol-sensitive receptors (Bosier et al., 2012), or altered
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arachidonate metabolism to reduce synthesis of cyclooxygenase-mediated products
(Fowler, 2007).
In contrast to URB597, PF3845 produced no effect on acid-induced depression
of ICSS. Although these results contrast with previous reports of PF3845
antinociception as discussed above (Ahn et al., 2009; Long et al., 2009; Kinsey et al.,
2010; Booker et al., 2012; Ghosh et al., 2012), they agree with the lack of PF3845
antinociception in the present assay of acid-stimulated stretching. The lack of effect with
PF3845 in the assay of pain-depressed behavior cannot be attributed to a lack of assay
sensitivity, because URB597 produced antinociception in the present study, and both
mu opioid agonists and nonsteroidal anti-inflammatory drugs have produced
antinociception in previous studies (Pereira Do Carmo et al., 2009; Kwilasz and Negus,
2012). Furthermore, as with URB597, PF3845 was tested at a time when initial
behavioral depressant effects on control ICSS had dissipated and could not confound
assessment of antinociception. The failure of PF3845 to produce antinociception in
assays of either pain-stimulated or pain-depressed behavior is also consistent with the
recent clinical failure of the structurally-related FAAH inhibitor PF7845 for the treatment
of osteoarthritis-related pain (Huggins et al., 2012).
Relationship of FAAH-inhibitor effects to fatty acid ethanolamine levels. There
was no clear association between drug effects on behavior and fatty acid ethanolamine
levels. Both URB597 and PF3845 produced qualitatively similar increases in AEA, OEA,
and PEA, consistent with their classification as FAAH inhibitors; however, these two
drugs produced different and sometimes diametrically opposite effects on behavior. For
example, both URB597 and PF3845 produced similar increases in brain levels of the
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endocannabinoid AEA after 240 min, but URB597 produced antinociception at this time
in both behavioral assays, whereas PF3845 produced pronociception (assay of acidstimulated stretching) or no effect (assay of acid-depressed ICSS). The only plausible
biochemical correlate of the different behavioral effects of URB597 and PF3845 was the
weaker effects of URB597 in increasing PEA brain levels. In support of this proposition,
PEA has been shown in some studies to increase the ability of AEA to activate TRPV1
ion channels (De Petrocellis et al., 2001; Ho et al., 2008; Garcia Mdel et al., 2009), and
this increased activity at TRPV1 might potentiate the effects of acid that have also been
shown to be mediated at least in part through TRPV1 (Tang et al., 2007). A more
parsimonious conclusion might be that antinociceptive effects of URB597 are mediated
at least in part by mechanisms other than FAAH inhibition and associated increased
levels of AEA, PEA, and/or OEA. This conclusion is also consistent with the finding that
antinociceptive effects of URB597 in the assay of acid-depressed ICSS were not
blocked by CB1R, CB2R, or PPAR-α antagonists, and that other effects of URB597 may
also be independent of CBR/PPAR-α activation by endocannabinoids/fatty acid
ethanolamines (Maione et al., 2006; Fowler, 2007; Bosier et al., 2012). For example,
URB597 been shown to decrease tyrosine hydroxylase in mouse brain through FAAHindependent mechanisms (Bosier et al., 2012) and also may alter arachidonate
metabolism to reduce synthesis of cyclooxygenase-mediated products (Fowler, 2007).
Another less parsimonious explanation is that multiple receptors may contribute to the
antinociceptive effects of URB597 in a synergistic fashion and that one or more of these
receptors is not activated to the same level by PF3845. Overall, the present results
suggest that URB597 is superior to PF3845 as a candidate analgesic for the treatment
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of acute pain, and that URB597 antinociception may be mediated in part by
mechanisms independent of FAAH inhibition, increased AEA levels, and CB1R
activation.
Abuse-related effects of FAAH inhibitors. As in the previous chapter with mixed
CB1R/CB2R agonists, FAAH inhibitors were also evaluated on ICSS performance in the
absence of noxious stimulation. Similar to the effects of the mixed CB1/CB2R agonists,
FAAH inhibitors did not produce facilitation of ICSS commonly interpreted as an abuserelated effect (Carlezon and Chartoff, 2007; Bauer et al., 2013). Rather, FAAH inhibitors
only produced rate-decreasing effects on control ICSS at higher doses and early pretreatment times. These results are consistent with a previous study, which also found
that URB597 and several other FAAH inhibitors only depressed ICSS in rats at similar
doses and pre-treatment times (Vlachou et al., 2006). Overall, these results are
consistent with the notion that FAAH inhibitors do not produce abuse-related effects
(Schlosburg et al., 2009; Alvarez-Jaimes and Palmer, 2011); however, these data
should be interpreted cautiously, as mixed CB1R/CB2R agonists that are abused by
humans also commonly do not produce abuse-related effects in this assay (Vlachou et
al., 2007; Kwilasz and Negus, 2012).

6.4. Effects of the CB2R agonist GW405833 on acute pain-stimulated and paindepressed behavior.
CB2R agonist effects on pain-stimulated behavior. The CB2R agonist
GW405833 was tested in the same assays of acid-stimulated stretching and aciddepressed ICSS that were used for studies with the other cannabinoids described
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above. In the assay of acid-stimulated stretching, a high dose of the CB2R agonist
GW405833 produced antinociception (i.e. 32 mg/kg), whereas lower doses (i.e. 3.2-10
mg/kg) did not. CB2R agonists including GW405833 have been shown to produce
antinociception in many preclinical assays of pain-stimulated behavior in rodents,
including mechanical allodynia following paw incision (LaBuda et al., 2005; Valenzano
et al., 2005), intraplantar injection of CFA (Valenzano et al., 2005; Whiteside et al.,
2005), or partial sciatic nerve ligation (Whiteside et al., 2005), as well as in assays of IP
p-phenylquinone (PPQ)-stimulated stretching (Anikwue et al., 2002), intraplantar
formalin-induced nociceptive behavior (Jafari et al., 2007), and intraplantar
carrageenan-induced changes in rear hind-paw weight bearing (Clayton et al., 2002;
Elmes et al., 2005). In addition to their antinociceptive effects, CB2R agonists have also
been shown to reduce paw edema after intraplantar injection of carrageenan (Clayton et
al., 2002; Elmes et al., 2005) and are thought to exert at least some of their antiinflammatory effects through inhibition of inflammatory cells such as microglia and
macrophages (Cabral et al., 2008; Wilkerson and Milligan, 2011). Indeed, studies have
shown that higher doses of CB2R agonists are commonly required to produce
antinociception in assays using acute noxious stimulation such as PPQ-induced
stretching or paw incision-induced mechanical allodynia versus more inflammatoryrelated stimuli such as CFA-induced mechanical allodynia (Anikwue et al., 2002;
Valenzano et al., 2005). These studies thus further support the notion that CB2R
agonists can produce antinociception through anti-inflammatory-related mechanisms,
and add to a growing body of literature that supports the antinociceptive properties of
CB2R agonists in nearly all assays of pain-stimulated behavior.
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CB2R agonist effects on pain-depressed behavior. As in the assay of acidstimulated stretching, the CB2R agonist GW405833 produced antinociception in the
assay of acid-depressed ICSS at a high dose of 32 mg/kg, whereas lower doses were
ineffective. No dose of GW405833 significantly altered responding for control ICSS in
the absence of the noxious stimulus, including the dose that produced antinociception;
thus, GW405833-induced antinociception in either assay cannot be explained by
nonspecific rate-altering effects of GW405833. The present study is the first to report on
effects of a CB2R agonist in an assay of pain-depressed behavior. In general, this study
supports results from assays of pain-stimulated behavior; however, further studies will
need to be conducted with different CB2R agonists and different noxious stimuli to
determine the specific circumstances under which CB2R agonists produce
antinociception in assays of pain-depressed behavior. The present results support the
proposition that CB2R agonists may be effective analgesics for the treatment of mild
acute pain in clinical settings.
Mechanisms of CB2R agonist-induced antinociception. Despite its primary
mechanism of action as a CB2R agonist, GW405833 did not produce CB2R-mediated
antinociception in either assay of acid-stimulated stretching or acid-depressed ICSS.
Rather, in the assay of acid-stimulated stretching, GW405833-induced antinociception
was blocked by the CB1R antagonist, rimonabant, but not by the CB2R antagonist,
SR144528. These results indicated GW405833-induced antinociception in the assay of
acid-stimulated stretching was mediated by CB1Rs but not CB2Rs. Indeed, studies
have shown that CB2R agonists administered at high doses produce CB1R-mediated
antinociception and/or cannabimimetic side-effects associated with activation of the
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CB1R (Anikwue et al., 2002; Valenzano et al., 2005; Whiteside et al., 2005).
Furthermore, drug development efforts at Merck found that two structurally different
classes of CB2R agonists (i.e. imidazopyridines and decahydroquinolines) were
ineffective in the preclinical assay of intraplantar CFA-induced mechanical allodynia in
rats, unless some functional activity at the CB1R was also present (Manley et al., 2011;
Trotter et al., 2011). The present data and existing literature thus fully support the notion
that CB2R agonists can produce CB1R-mediated antinociception in assays of painstimulated behavior, especially when administered at high doses, and some studies
even suggest CB1R activation is essential for CB2R agonist-induced antinociception.
In contrast to the assay of acid-stimulated stretching, in the assay of aciddepressed ICSS, GW405833 produced non-CB1R/CB2R-mediated antinociception.
These results suggest that GW405833-induced antinociception in the assay of aciddepressed ICSS is mediated by either a) unknown cannabinoid targets and/or b) known
or unknown non-cannabinoid-targets. For example, GW405833 has been shown to
interact with a known putative cannabinoid receptor target, G-protein coupled receptor
55 (GPR55) (Anavi-Goffer et al., 2012). CB2R agonists have also been shown to
produce off-target effects mediated by mu-opioid receptors (Ibrahim et al., 2005;
Whiteside et al., 2005) and TRPV1 (Schuelert et al., 2010). Further studies will need to
be conducted to determine mechanisms of GW405833-induced antinociception in the
assay of acid-depressed ICSS, as well as CB2R agonist effects on other paindepressed behaviors in general. Nonetheless, these results demonstrate that a CB2R
agonist can function through two different non-CB2R-mediated mechanisms to produce
different antinociceptive effects. Moreover, these results demonstrate that neural
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pathways mediating acid-stimulated stretching and acid-depressed ICSS can be
dissociated, as we have also demonstrated in a previous study (Kwilasz and Negus,
2012), and could suggest that they involve different components of pain-processing.
Although neural pathways are incompletely mapped (Willis, 2009), noxious stimulation
by an acute IP injection of lactic acid likely involves spinal and supraspinal pathways of
pain-processing (Price, 2002; Borsook and Becerra, 2011; Jarcho et al., 2012).
GW405833 thus appears to alter the components of pain-processing that mediate both
acid-stimulated stretching and acid-depressed ICSS. Taken together, these results
support complementing assays of pain-depressed behavior with assays of painstimulated behavior in preclinical analgesic drug development and suggest that CB2R
agonists may be useful for the treatment of acute pain. Moreover, these results suggest
that the therapeutic effects of CB2R agonists in acute pain settings may not be solely
related to their activity at CB2Rs.
Abuse-related effects of CB2R-agonists. To assess abuse-liability as in previous
chapters, effects of GW405833 on control ICSS responding were assessed in the
absence of noxious stimulation. Similar to results with mixed CB1R/CB2R agonists and
FAAH inhibitors, GW405833 did not produce increased responding for control ICSS,
which is commonly interpreted as abuse-related effect (Carlezon and Chartoff, 2007;
Bauer et al., 2013). This is the first study to report on the effects of a CB2R agonist in
an assay of ICSS. These results support results from other studies that have
demonstrated CB2R agonists lack abuse-liability and the side effect profile commonly
associated with activation of the CB1R (Anikwue et al., 2002; Valenzano et al., 2005;
Whiteside et al., 2005; Karst and Wippermann, 2009). Furthermore, a recent study has

135
demonstrated that CB2R agonists may be an effective treatment for cocaine abuse,
demonstrating that CB2R agonists can block cocaine-induced self-administration and
associated increases in dopamine in the nucleus accumbens (Xi et al., 2011), which are
also commonly interpreted as abuse-related effects (Carlezon and Chartoff, 2007; Blum
et al., 2011; Bauer et al., 2013). In summary, CB2R agonists do not produce abuserelated effects in preclinical studies, and some studies suggest they may useful to block
abuse-related effects of other drugs.

6.5. Effects of THC on acute and repeated LPS-induced stimulation of mechanical
allodynia and depression of ICSS.
LPS effects on pain-stimulated behavior. In these studies, LPS, a constituent of
bacterial cell walls, was administered IP as a pro-inflammatory noxious stimulus to
stimulate mechanical allodynia. Daily LPS administration produced mechanical
allodynia at 30 min but not at 100 min. However, this effect was variable between
subjects and only persisted for two of the seven days of LPS administration.
Interestingly, a trend for LPS to produce mechanical allodynia at the later time point of
100 min was also observed, and this effect began on the third day of LPS treatment and
persisted for the remaining three days of the experiment. This effect coincided with a
dramatic tolerance to the “sickness-like” signs produced by LPS on the first two days of
administration (observed by the experimenter at the later 100 min time point, although
not quantified). These signs included unkempt fur with mild porphyrin staining, hunched
posture, weak muscle tone, sedation, and ptosis, which appeared to interfere with
behavioral responses to mechanical stimulation of the hind paw. Most animals in this
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group did not respond to any Von Frey filament even up to those that lifted their paw
due to the force applied by the filament alone while showing these signs. This could
suggest that animals may have displayed mechanical allodynia at this later time point
on the first two days of LPS administration if these sickness signs had not interfered,
although this is a purely speculative suggestion. These results are in agreement with
previous studies, which have shown that IP administration of LPS produces mechanical
allodynia in a Von Frey paw-withdrawal procedure (Cahill et al., 1998) and hyperalgesia
in a warm-water tail-flick procedure in rats (Watkins et al., 1994).
In contrast to the group that received chronic LPS treatment, acute administration
of LPS failed to produce mechanical allodynia in a separate group of rats. In this group,
LPS was administered acutely a total of three times with a two-week interval between
doses. One possibility for this discrepancy may be related to differences in prior
exposure to inflammatory-related noxious stimuli between the two experimental groups.
For example, previous studies have shown that mechanical allodynia following IP LPS
is dependent upon a prior immunological insult, such as an earlier injection of LPS
(Cahill et al., 1998), or surgical procedure, such as laparotomy (Hains et al., 2010). Due
to different methodologies between studies, the first group that received chronic LPS
treatment had surgically-implanted intracranial electrodes for ICSS procedures, which
have been shown to produce associated neuroinflammation (Hirshler et al., 2010).
Furthermore, these rats also participated in daily ICSS sessions, which also may have
influenced ongoing neuroinflammation. In contrast, rats that received acute LPS
treatment did not have intracranial implants, and two-week intervals between LPS
injections may have been too long to sustain an immunological “priming” effect that has
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been reported to exacerbate responses to LPS in other studies. Collectively, these
studies suggest that subject- and/or other experimental-related variables considerably
influenced the results. Moreover, LPS was a rather weak and unreliable noxious
stimulus, although a more rigorous manipulation of subject-, time-, and dose-related
variables that determine LPS-induced mechanical allodynia could reveal more useful
results.
LPS effects on pain-depressed behavior. In these studies, IP LPS served as the
noxious stimulus to decrease ICSS. The group of animals that received daily LPS
injections displayed significantly decreased responding for ICSS at the later 100 min
time point on days one, two, and four of the seven-day chronic LPS regimen; however,
this effect was rather unreliable across all animals and other time points. For example,
ICSS was also significantly decreased at the early 30 min time point on day two. The
animals also displayed apparent “sickness-like” behaviors on the first two days of LPS
treatment at the later 100 min time point (described in the previous section). This
“sickness-like” behavior seemed to correlate with the most profound decreases in ICSS
behavior. In a separate group of rats, acute LPS administration also depressed ICSS
behavior 90 min post-LPS administration, albeit this effect was also weak relative to the
effects of IP acid and was not reliable between subjects or when administered multiple
times at a 2-week dosing interval. LPS has been shown in previous studies to stimulate
pro-inflammatory cytokine production, and previous studies have shown that LPS and
cytokine administration can depress a wide variety of different behaviors including ICSS
(Anisman et al., 1996; Anisman et al., 1998; Borowski et al., 1998; Barr et al., 2003; van
Heesch et al., 2013), feeding (Kubera et al., 2013), and social interaction (Konsman et
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al., 2008). The results of the present study are thus concordant with previous studies
and suggest that LPS can be used as a pro-inflammatory noxious stimulus to decrease
behavior. However, the present results also suggest that LPS effects are rather weak
compared to an IP acid noxious stimulus and unreliable across subjects and repeated
treatments.
THC effects on LPS-induced nociceptive behaviors. It was impossible to
determine whether THC was able to produce antinociception in the assay of LPSstimulated mechanical allodynia, because LPS did not produce mechanical allodynia in
the group of animals tested with THC. THC also did not produce evidence of
antinociception in the assay of LPS-induced depression of ICSS; however, LPS effects
were unreliable in that they did not depress behavior in all animals and were not stable
when administered a second and third time at two-week dosing intervals. These
properties of LPS effects on ICSS behavior made assessment of THC effects difficult.
For example, LPS only significantly decreased ICSS on the first and third
administrations, but not on the second administration. Previous studies have shown that
THC and other cannabinoids produce robust anti-inflammatory effects and block LPSinduced stimulation of pro-inflammatory cytokines (Puffenbarger et al., 2000; Roche et
al., 2006), and these effects are thought to be related to their ability to produce
antinociception and anti-inflammatory effects in preclinical assays of inflammatoryrelated pain (Croxford and Yamamura, 2005; Burstein and Zurier, 2009; Stein and
Machelska, 2011). The present results cannot accurately conclude whether THC effects
in the assay of LPS-depressed ICSS agree with previous studies; however, they do
suggest a possible disagreement, showing THC may be ineffective in the assay of LPS-
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depressed ICSS. These results should be reproduced under more stable experimental
conditions to accurately discern whether THC produces antinociception in the assay of
LPS-depressed ICSS.

6.6. General Discussion and Summary
In chapters 2-4, an IP injection of lactic acid served as an acute noxious stimulus
to stimulate stretching or depress ICSS. Cannabinoids produced antinociception in all
assays of acid-stimulated stretching, with the exception of the FAAH inhibitor PF3845
for unknown reasons. In contrast, cannabinoids displayed no efficacy or submaximal
efficacy to produce antinociception in the assay of acid-depressed ICSS, and even
drugs that produced weak antinociception (i.e. FAAH inhibitor URB597 and CB2R
agonist GW405833) did not produce their effects through CBRs. In chapter 5,
chronic/acute IP injections of LPS served as chronic/acute inflammatory-related noxious
stimuli to stimulate mechanical allodynia or depress ICSS. However, the effects of LPS
on both endpoints were weak compared to an IP acid injection and unreliable across
subjects and repeated treatments, which made prediction of THC effects on LPSinduced nociceptive behaviors difficult. In general, these data are concordant with the
clinical data on cannabinoid effects on acute pain (Rice, 2006; Karst et al., 2010; Kraft,
2012), but data from the LPS studies are not adequate to predict cannabinoid effects in
an assay of inflammatory-related pain-depressed behavior.
Implications for preclinical strategies of drug development. Preclinical assays of
pain and analgesia play a critical role in analgesic drug development, but there is a
growing appreciation that drug effects in conventional preclinical assays of pain-
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stimulated behavior are often poor predictors of clinical analgesic efficacy in humans
(Blackburn-Munro, 2004; Negus et al., 2006; Whiteside et al., 2008; Mogil, 2009).
Results with THC and CP55940 have illustrated this discordance most clearly insofar as
mixed cannabinoid agonists produce robust and reliable antinociception in most assays
of acute pain-stimulated behavior but little or no analgesia against acute pain in humans
(Rice, 2006; Karst et al., 2010; Kraft, 2012). For example, oral delivery of THC or other
cannabinoids lacked analgesic efficacy or exacerbated pain in most well-controlled
clinical studies of postoperative or acute experimental pain [(Raft et al., 1977; Buggy et
al., 2003; Naef et al., 2003; Beaulieu, 2006; Kraft et al., 2008; Klooker et al., 2011); for
the lone exception, see (Campbell et al., 2001)]. Similarly, smoked marijuana at doses
up to those producing untoward motor/cognitive/subjective effects produced little or no
change in sensitivity to acute thermal, mechanical, or chemical noxious stimuli in clinical
laboratory studies, and as with oral cannabinoids, pain ratings were sometimes
worsened by smoked cannabis (Greenwald and Stitzer, 2000; Wallace et al., 2007).
Moreover, the failure of PF3845 to produce antinociception in assays of either painstimulated or pain-depressed behavior is also consistent with the recent clinical failure
of the structurally-related FAAH inhibitor PF7845 for the treatment of osteoarthritisrelated pain (Huggins et al., 2012). The present studies suggest that preclinical assays
of pain-depressed behavior may yield results that complement results from more
conventional assays of pain-stimulated behavior and improve predictions of clinical
cannabinoid effects. As such, these studies support the utility of assays of paindepressed behavior in development of cannabinoid analgesics.

141
Particularly interesting are the effects of the FAAH inhibitor URB597 and the
CB2R agonist GW405833 in the assay of pain-depressed behavior, which produced
antinociceptive effects mediated by different mechanisms than in the assay of painstimulated behavior. Both URB597 and GW405833 produced CB1R-mediated
antinociception in the assay of pain-stimulated behavior but produced non-CBRmediated antinociception in the assay of acid-depressed ICSS. URB597-induced
antinociception was also not mediated by PPAR-α, another related target of FAAH.
These results demonstrate the potential for assays of pain-depressed behavior to reveal
potential new mechanisms of antinociception/analgesia produced by putative
cannabinoid drugs.
Summary, conclusions, and future directions. The goal of this study was to
characterize the efficacy of cannabinoid drugs on pain-stimulated versus paindepressed behavior. Although some of the drugs tested produced CB1R-mediated
antinociception in the assay of pain-stimulated behavior (i.e. THC, CP55940, URB597
and GW4085833), these drugs either failed to produce antinociception in the assay of
pain-depressed behavior (i.e. THC and CP5594), or they produced non-CB1/2Rmediated antinociception in the assay of pain-depressed behavior (i.e. URB597 and
GW405833). These results challenge prevailing notions about the efficacy and
mechanisms of cannabinoids to produce analgesia. Consequently, one conclusion from
these studies is that assays of pain-depressed behavior provide a useful complement to
assays of pain-stimulated behavior, as they are able to measure behaviors that have
different underlying substrates than those underlying assays of pain-stimulated
behavior. The substrates of pain-depressed behavior are not fully understood, but are
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thought to involve traditional pain pathway interaction with reward-related brain areas,
with the ultimate result of noxious stimulation decreasing mesolimbic DA. This suggests
that the inclusion of assays of pain-depressed behavior in preclinical analgesic drug
development might provide the ability to discover drugs that are effective against
substrates underlying pain-depressed behavior. Moreover, these studies may ultimately
lead to a more thorough characterization of the substrates of pain, which may
encompass other facets of pain besides sensory components (e.g. affective and/or
cognitive) that are not measured in traditional assays of pain-stimulated behavior. This
will lead to development of preclinical assays of pain that are more predictive of clinical
outcome, and will ultimately lead to more efficient analgesic drug development.
The research in this dissertation has identified several cannabinoid drugs that
block pain-induced depression of behavior; however, the mechanisms underlying the
effects of these drugs have not yet been determined. These studies investigated the
traditional receptor mechanisms by which these drugs are thought to act but were
unsuccessful in determining a mechansim. The model in Figure 1.4 will thus require
revision to include non-CBR-mediated mechanisms of antinociception that are mediated
by URB597 and GW405833. A common receptor target of these two compounds is
TRPV1 (Maione et al., 2006; Schuelert et al., 2010), which may be included in the
model in Figure 1.4. TRPV1 is present on primary afferent nociceptors and may be
desensitized by activation by cannabinoids, which could result in an overall decrease in
sensory transmission (Ralevic and Kendall, 2009). Some future studies that could be
done would be to attempt to block the effects of URB597 and GW405833 with a TRPV1
antagonist, such as capsazepine, and to try to recapitulate the effects these drugs with
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a TRPV1 agonist, such as capsaicin. Capsaicin has already been shown to desensitize
primary afferent nociceptors following activation of TRPV1 (Brederson et al., 2013),
providing a proof of concept for this mechanism. Moving forward, TRPV1 will be an
important mechanism to test, however, future studies may also be necessary to
determine other mechanisms underlying the antinociceptive effects of these drugs. Until
future studies can more extensively characterize the effects of other cannabinoidrelated drugs on acid-induced pain-related behavior as well as behavior stimulated and
depressed by other noxious stimuli, the results of these studies should also be qualified
by their experimental parameters.
One important future study that should be done is to test other CB2R agonists
besides GW405833, as well as other FAAH inhibitors besides URB597 and PF3845, in
the assays of acid-stimulated stretching and acid-depressed ICSS. These studies will
help to determine if the antinociceptive effects of these drugs are common between
CB2R agonists/FAAH inhibitors or only specific to GW405833 and URB597. From here,
it would be useful to determine commonalities or differences between the effects of
drugs that produce antinociception in assays of pain-depressed behavior, and then
individually probe each one of these mechanisms as specifically as possible to
determine if they can alter the effects of these drugs. Ultimately, once the mechanisms
underlying the antinociceptive properties of these drugs are relatively understood, drugs
could be developed if not already available to test if these mechanisms are sufficient to
produce antinociception in both assays of pain-stimulated and pain-depressed behavior.
If promising, this could lead to clinical trials and effective new analgesics with reduced
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side effects, improved efficacy, and/or that treat refractory pain conditions. These new
analgesics may or may not have cannabinoid-related mechanisms.
Another direction to take this line of research would be to assess other noxious
stimuli. We made an attempt to study another noxious stimulus in this dissertation (i.e.
IP LPS); however under the experimental parameters that we studied, IP LPS was a
rather poor noxious stimulus compared to IP lactic acid. We had hypothesized that
cannabinoid drugs may be more effective to produce antinociception against a highly
inflammatory-related noxious stimulus such as IP LPS, versus IP lactic acid. The results
of our studies were inconclusive; however future studies could examine different doses
of LPS as well as different subject-related variables, such as whether “priming” the
animals with a noxious stimulus is important in producing future pain-related behaviors.
Other noxious stimuli besides LPS and lactic acid must also be studied, and to date
other studies have also shown that complete Freund’s adjuvant produces pain-related
depression of locomotion, rearing, and wheel-running behavior (Matson et al., 2007;
Cobos et al., 2012). Future studies examining different noxious stimuli should first
examine whether other acute, inflammatory, neuropathic, and cancer-related pain
manipulations produce depression of behavior and other signs of pain-stimulated
behavior alone. Next, studies should determine whether cannabinoid-related drugs can
either block/reverse the effects of the noxious stimulus on some behavior. If a noxious
stimulus does not produce depression of behavior alone, cannabinoid-related drugs
could still be tested in combination with this noxious stimulus to determine if the
combination alters the effects of cannabinoids on various cannabinoid-mediated
behaviors. Other studies could determine whether cannabinoids were effective by other
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routes of administration, including the inhaled route, which might prove to be more
similar to consumption of smoked marijuana. Lastly, other behaviors not currently
considered pain-related behaviors should be tested for their sensitivity to noxious stimuli
and analgesic drug treatment, as they may also prove to be useful new assays of painrelated behavior. These new assays may encompass other facets of pain not measured
by assays of pain-stimulated or pain-depressed behavior, further expanding our ability
to predict the clinical efficacy of candidate analgesics.
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